Compositions and methods for treatment, diagnosis, and prognosis of leukemia based on leukemia-specific gene fusions, mutations, and variants

WO2024186944A3PCT designated stage expired Publication Date: 2024-11-14FRED HUTCHINSON CANCER CENT
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/018747
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-06
Filing Date
2024-03-06
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current diagnostic and testing approaches for leukemia, particularly in low- and middle-income countries, are hindered by the high cost, slowness, and complexity of molecular testing, leading to delayed initiation of targeted treatments due to the lack of access to rapid and inexpensive molecular testing for leukemia-associated genomic aberrations.

Method used

A method involving an endonuclease-guide RNA complex to generate long-chain DNA molecules, which are sequenced without amplification using long-range sequencing, allowing for the precise characterization of leukemia gene mutations and aberrations, enabling rapid and accurate diagnosis and treatment decisions.

Benefits of technology

This approach facilitates rapid, cost-effective, and accurate characterization of leukemia-associated genomic aberrations, reducing the time to treatment and improving clinical outcomes by providing accessible and portable molecular diagnostics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024018747_14112024_PF_FP_ABST
    Figure US2024018747_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Methods, compositions, computational methodologies, and kits for cost-effective and improved detection and characterization of leukemia mutations for treatment of leukemia. Leukemias frequently present with recurrent gene fusions, which can be drivers of disease pathophysiology. The disclosed approaches do not utilize amplification of polynucleotides, lowering energy requirements and current financial and socioeconomic barriers limiting access to diagnostics and treatments. The disclosed approaches facilitate identification of leukemia genomic variants and help stratify diseases by risk, facilitating improved therapy choices, including for cost-sensitive communities with limited access to biomedical testing services.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS AND METHODS FOR TREATMENT, DIAGNOSIS, AND PROGNOSIS OF LEUKEMIA BASED ON LEUKEMIA-SPECIFIC GENE FUSIONS, MUTATIONS, AND VARIANTSCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 488737, filed March 06, 2023, the disclosure of which is incorporated herein by reference in its entirety.STATEMENT REGARDING SEQUENCE LISTING

[0002] The Sequence Listing XML associated with this application is provided in XML format and is hereby incorporated by reference into the specification. The name of the XML file containing the sequence listing is 1896-P68WO Sequence Listing. xml. The XML file is 138,745 bytes; was created on March 06, 2024; and is being submitted electronically via Patent Center with the filing of the specification.BACKGROUND

[0003] Leukemia is a cancer of the blood, characterized by the rapid growth of abnormal blood cells. Acute myeloid leukemia (AML) is a complex form of leukemia that can involve multiple diagnostic approaches for management and prognostication.

[0004] Current classification of myeloid malignancies is largely based on molecular and genetic aberrations. Recurrent gene rearrangements are present in 30-40% of acute myeloid leukemias (AML), and in a subset of AML well described driver fusions suffice to diagnose leukemias such as PML;;RARA, CBF-AML (RUNX1;;RUNX1T1 and CBFB;;MYH11), among others described by the World Health Organization (WHO) and the International Consensus Classification. These fusion genes confer certain clinical and biological characteristics as drivers of leukemogenesis that can assist in prognosis stratification and inform treatment decisions. This can be especially relevant in developing countries with novel target therapies available since included in the WHO list of essential medicines may best direct the use of resources. Examples include tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CML) that block BCR-ABL kinase activity, anddifferentiation therapy with all-trans retinoic acid (ATRA) in acute prom yelocy tic leukemia (API .) targeting the (PML-RARA) fusion.

[0005] Typically, fusion genes are detected by fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) assays, or next generation sequencing (NGS). NGS is an attractive technology because it should be able to detect a variety of genetic mutations found in leukemia, including fusions, insertions, deletions, and point mutations in oncogenic genes. However, conventional NGS also has technical hurdles (short sequencing reads, introduction of false positive errors due to library preparation) as well as hardware issues (expensive machines, complicated bioinformatics). These issues make NGS hard to employ readily in the low and middle-income country (LMIC) settings.

[0006] Furthermore, prior diagnostic and testing approaches for leukemia, including cytogenetic and molecular studies, are costly and slow7, and typically require tw7o to four weeks to be completed. These approaches also typically involve amplification of DNA sequences and require time, expertise, complexity, and expense, as well as a full bioinformatics support infrastructure. The inaccessibility of these elements results in a significant delay in the diagnostic and testing phase, which in turn delays initiation of targeted treatments. This can lead to further progression of the disease. As such, a key challenge in clinical management of leukemia includes the lack of access to rapid, inexpensive molecular testing to quickly determine the presence of recurrent genomic aberrations that are commonly seen in leukemia. This testing could efficiently guide the care team toward targeted treatments, based at least in part on the genomic aberrations identified.

[0007] Therefore, there is a need for compositions and methods for rapid, cost- effective, accurate, and precise characterization of leukemia-associated genomic aberrations for more effective treatment of leukemia. The present disclosure addresses these and other long-felt and unmet needs in the art.SUMMARY

[0008] This summary' is provided to introduce a selection of concepts in a simplified form that are further described below7in the Detailed Description. This summaryis not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0009] In an aspect, the disclosure provides a method of treating a subject with a leukemia, the method comprising: contacting a DNA molecule that comprises a leukemia gene mutation or alteration with an endonuclease-guide RNA complex to generate a long- chain DNA molecule that comprises the leukemia gene mutation or alteration; sequencing, without amplification of the long-chain DNA molecule, the long chain DNA molecule with a long-range sequencing method to produce a sequence read; computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read, wherein the characteristic corresponds to the leukemia; and administering a leukemia treatment to the subject based on the characteristic.

[0010] In an aspect, the disclosure provides a method of diagnosing a subject with a leukemia, the method comprising: contacting a DNA molecule that comprises a leukemia gene mutation with an endonuclease-guide RNA complex to generate a long-chain DNA molecule that comprises the leukemia gene mutation; sequencing, without amplification of the long-chain DNA molecule, the long-chain DNA molecule with a long-range sequencing method to produce a sequence read; computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read, wherein the characteristic corresponds to the leukemia; and diagnosing the subject with the leukemia based on the characteristic.

[0011] In embodiments, the leukemia comprises acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), myeloproliferative neoplasm (MPN), mixed-lineage leukemia (MLL), or any combination thereof.

[0012] In embodiments, the characteristic comprises a genetic mutation, a deletion, an insertion, a substitution, a frameshift, a breakage, a fusion, a genetic phase change, or any combination thereof.

[0013] In embodiments, the leukemia gene mutation comprises: an ASXL transcriptional regulator 1 (ASXL1) mutation, an fms related receptor tyrosine kinase 3 (FLT3) mutation, a CCAAT enhancer binding protein alpha (CEBPA) mutation, a nucleophosmin 1 (NPM1) mutation, an isocitrate dehydrogenase (NADP(+)) 1 / 2 (IDH1 / 2) mutation, a calreticulin (CALR) mutation, a KIT proto-oncogene receptor tyrosine kinase (KIT) mutation, a Janus kinase 2 (JAK2) mutation, a tumor protein P53 (TP53) mutation, a t( 15; 17)(q24.1 ;q21.2) PML-retinoic acid receptor alpha (RARA) translocation that forms a fusion gene, a t(8;21)(q22;q22. 1) RUNX family transcription factor 1 (RUNX1)- RUNX1 partner transcriptional co-repressor 1 (RUNX1T1) translocation that forms a fusion gene, a translocation between core-binding factor subunit beta (CBFB)-myosin heavy chain 11 (MYH11) (invl6) that forms a fusion gene, a t(6;9) translocation between genes DEK protooncogene (DEK)-nucleoporin 214 (NUP214) that forms a fusion gene, a t(l;22) translocation between genes DEK protooncogene (DEK) and nucleoporin 214 (NUP214) that forms a fusion gene, a translocation t(9;22)(q34;ql 1) between breakpoint cluster region (BCR) and Ableson murine leukemia viral oncogene homolog 1 (ABL1) that results in a fusion gene, a non-receptor tyrosine kinase (ABL1) mutation, a translocation between nucleoporin 98 and 96 precursor (NUP98) to nuclear receptor binding SET domain protein 1 (NSD1) that results in a fusion gene, an MLL rearrangement that results in a fusion gene, or any combination thereof

[0014] In embodiments, the leukemia gene mutation comprises: the PML-RARA mutation, the ABL1 mutation, the KILL mutation, a fusion that involves at least one gene rearrangement of one or more genes of any one of Embodiments 1-5, or any combination thereof.

[0015] In embodiments, the endonuclease-guide RNA complex comprises a guide RNA (gRNA) comprising a sequence selected from SEQ ID NOs: l~70,

[0016] In embodiments, the long-chain DNA molecule comprises a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

[0017] In embodiments, the long-chain DNA molecule is not amplified by any polymerase chain reaction (PCR) technique or any isothermal DNA amplification technique.

[0018] In embodiments, one or more leukemia treatment compositions is administered to the subject for treatment of the leukemia.

[0019] In embodiments, the one or more leukemia treatment compositions comprises an FLT3 inhibitor, an IDH1 inhibitor, an IDH2 inhibitor, a Jak2 inhibitor, an HD AC inhibitor, all-transretinoic acid (ATRA), an anti-CD33 targeted therapeutic compound, a tyrosine kinase inhibitor, a chemotherapeutic compound, a DOT IL inhibitor, or any combination thereof.

[0020] In embodiments, the FLT3 inhibitor comprises midostaurin, gilteritinib, or both.

[0021] In embodiments, the IDH1 inhibitor comprises ivosidenib.

[0022] In embodiments, the IDH2 inhibitor comprises enasidenib.

[0023] In embodiments, the one or more leukemia treatment compositions comprises the Jak2 inhibitor and the HD AC inhibitor.

[0024] In embodiments, the one or more leukemia treatment compositions comprises the ATRA and the anti-CD33 targeted therapeutic compound.

[0025] In embodiments, the tyrosine kinase inhibitor comprises dasatinib, imatinib, midostaurin, or any combination thereof.

[0026] In an aspect, the disclosure provides circuitry configured for performance of a method, the method comprising: downloading, from a cloud computing device, genomic data that is relevant to leukemia; electronically storing raw sequence data to a non-transitory computer-readable storage medium as non-transitory data; basecalling the non-transitory data that, comprises the raw sequence data to produce nucleotide base data that, correspond to nucleotide bases of a sequenced long chain DNA molecule, indexing and aligning the nucleotide base data with alignment data and gene definition data for analignment; computing, from the alignment, one or more leukemia gene aberrations of the sequenced long-chain DNA molecule, wherein the one or more leukemia gene aberrations is inclusive of leukemia gene aberrations that are proximal and distal to a leukemia gene breakpoint; and depicting, with an electronic display, the alignment and the one or more leukemia gene aberrations of the sequenced long-chain DNA molecule.

[0027] In embodiments, at least the computing of the one or more leukemia gene aberrations is performed by a Biodepot Fusion Finder (BFF) software that configures the circuitry’ to compute fusion enrichment and on-target enrichment statistics for the computing of the one or more leukemia gene aberrations.

[0028] In an aspect, the disclosure provides one or more computational devices or systems comprising the circuitry’.

[0029] In an aspect, the disclosure provides a guide RNA comprising a sequence as set forth in any one of SEQ ID NOs: 1-70.

[0030] In embodiments, the guide RNA is configured to bind a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

[0031] In an aspect, the disclosure provides an endonuclease-guide RNA complex comprising the guide RNA.

[0032] In an aspect, the disclosure provides a composition comprising the endonuclease-guide RNA complex.

[0033] In an aspect, the disclosure provides a kit comprising the composition and an instructional material configured to instinct a user for a use of the kit in performance of a method.

[0034] In an aspect, the disclosure provides a probe for detecting a leukemia gene mutation, the probe comprising a sequence as set forth in any one of SEQ ID NOs: 1-70.

[0035] In embodiments, the probe binds to a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

[0036] In an aspect, the disclosure provides a library' comprising a plurality of endonuclease-guide RNA complexes, wherein each endonuclease-guide RNA complex comprises a guide RNA that targets DNA that comprises a leukemia gene mutation.DESCRIPTION OF THE DRAWINGS

[0037] The foregoing aspects and many of the attendant advantages of this disclosure will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:

[0038] FIGs 1A-1B show an example chemistry and bioinformatics workflow of rapid single-molecule long-read sequencing, according to aspects of the disclosure. Genomic DNA may contain a target fusion gene. The CRISPR-Cas9 system binds via specific guideRNA (gRNA) designed to enrich for DNA containing regions of interest. The library preparation does not undergo any amplification and includes dA tailing, adapter ligation, and a clean-up before being loaded onto a sequencing flow cell. On the flow cell, libraries are sequenced by nanopores. The Biodepot-workflow'-builder (Bwb) platform takes the input sequencing data in FAST5 format, performs quality control, base calling, and alignment. After alignment, different fusion finder tools were applied, including LongGF and the Biodepot Fusion Finder (BFF), before visualizing the results using the Integrative Genomics Viewer (IGV) for confirmation and interpretation.

[0039] FIGs 2A-2C show an example fusion detection bioinformatics workflow and output, according to aspects of the disclosure. FIG. 2A show's an example screenshot of a Bwb workflow showing the display interface, including the custom Biodepot Fusion Finder (BFF) and LongGF widgets. FIG. 2B shows example enrichment statistics as fusion enrichment and on-target enrichment. FIG. 2C shows an example alignment that can be viewed on Integrative Genomics Viewer (IGV) based on a BAM file generated from minimap2. This example shows a t(9;22) BCR::ABL1 fusion in a primary specimen. Reads spanning the breakpoint are indicated with the same corresponding indication, in alignment to both genes.

[0040] FIGs 3A-3B show an example of the time needed to obtain 3 fusion supporting reads, according to aspects of the disclosure. FIG. 3 A show's the time to 3 fusionsupporting reads seen in the cell lines samples. FIG. 3B shows time to 3 fusion supporting reads seen in patient samples. Details of specific times are listed in Table 4.

[0041] FIGs 4A-4D show an example genomic BCR-ABL1 breakpoint identified in a primary specimen by long-read sequencing, according to aspects of the disclosure. The breakpoint was captured with the disclosed amplification-free enrichment protocol and long-read sequencing. Reads capturing the breakpoint were up to approximately 23Kb long; 2Kb in BCR, chromosome 22, and 21Kb in ABL1, chromosome 9. FIG. 4A shows an example schematic representation of the breakpoint captured with an amplification free enrichment protocol and long-read sequencing. Reads capturing the breakpoint are up to approximately 23Kb long and represented in the graph by the solid and broken line: 2KB in BCR, chromosome 22, and 21KB in ABLI, chromosome9. FIG. 4B shows an example nanopore sequence IGV visualization, showing the alignment of multiple sequences with ABLI (upper arrow). The fragment marked by the lower arrow does not align with ABL1 and corresponds to BCR. FIG. 4C show's an example agarose gel electrophoresis (2% agarose) of PCR amplified product using patient specific primers designed after breakpoint detection. The gel shows the patient sample in lane 1 and a BCR- AB 1 cell line (KCL22) in lane 2. FIG. 4D show's an example confirmation of the patient specific breakpoint by Sanger sequencing.

[0042] FIG. 5 show's an example bioinformatics pipeline for fusion detection, according to aspects of the disclosure. The pipeline utilizes a combination of specific containerized programs for detection of fusions via scripting in the programming language R. Reads that span a fusion gene can align to coordinates in both parts of the fusion. As an example, one can use a manual / IGV based method that examines the genes of interest and maps alternate alignments for each read, which can identify specific reads that map to coordinates spanning a set of known breakpoints. Additional software-based features can be implemented to create computational solutions for any such manual method of fusion detection.

[0043] FIG. 6 shows an example view of genes BCR and ABL1 including crRNAs (vertical solid lines) and breakpoints (vertical dotted lines), according to aspects of the disclosure.

[0044] FIG. 7 shows an example method of diagnosing or treating a subject, with a leukemia, according to aspects of the disclosure. The example method 1 includes contacting 2 a DNA molecule with an endonuclease guide RNA complex, sequencing 3 the resultant long-chain DNA molecule without amplification, computing 4 a characteristic of the leukemia gene fusion, and in the case of a method of treating the subject, administering 5 a leukemia treatment to the subject. The disclosed methods provide cost-effective and accurate diagnostic methods and kits for reduction of time to treatment.DETAILED DESCRIPTION

[0045] The advancement of long-read sequencing technologies has enabled the sequencing of continuous single DNA or RNA molecules up to tens to hundreds of kilobases (kb) long. Ongoing improvements in Nanopore® sequencing accuracy have reduced error rates to less than 5%, but remain higher than those for Illumina® and Ion Torrent® platforms, which are used in clinical laboratories. Long-read sequencing has also made an impact on the understanding of the pathobiology of various diseases, and its impact should increase as the quality of sequencing improves and becomes more accurate.

[0046] As described herein, the addition of CRISPR-Cas9 for targeted enrichment concentrates the regions of interests prior to sequencing by Nanopore® without requiring amplification steps significantly improves sequencing time and efficiency. In addition, the portability and affordability of the Nanopore® sequencer MinlON® and Flongle®, are useful to impact the clinical field, especially in the areas of low resources. The disclosure also provides analytical software featuring standardized parameters to aid in translation into clinical diagnostics. Implementation of such a portable platform with reduced cost and cloud-based, on demand analysis workflow in developing countries would enable testing centers to provide sequencing without investing in a computing or bioinformatics infrastructure thus bridge the gap between diagnosis and tailored treatment administration.

[0047] In various aspects, the disclosure provides comprehensive, personalized, and rapid diagnostic assays to improve clinical outcomes for acute leukemia. Acute myeloid leukemia (AML) is the most, common type of blood cancer, but despite having one of the most successful treatments available, mortality rates remain highly variable, ranging from 10 to 90% due to different prognostic subtypes. AML is characterized by a widevariety of distinct cytogenetic and molecular subgroups that impact disease response and survival. Despite the growing knowledge of the molecular etiologies of AML and other forms of leukemia, current diagnostic approaches, including morphology, flow cytometry, molecular PCR and NGS assays, or cytogenetics with fluorescence in situ hybridization (FISH), are costly and slow. These assays also need high complexity laboratories, skilled personnel, and full bioinformatics support infrastructure. Many hospitals cannot offer true “STAT” testing due to its high cost, personnel requirements, and low volume testing. This is relevant at least because delays in diagnosis are contributing factors to early death and increased morbidity in some types of leukemia such as acute promyelocytic leukemias. The disclosure provides novel and improved approaches that leverage the utility of fusion genes as therapeutic targets and diagnostic or prognostic biomarkers in a clinical setting.

[0048] As NGS is increasingly a standard part of leukemia management, its limitations are becoming more apparent. These include potential phasing errors, increased artifacts, and mis-mapping from short reads; variant calls that are based on allelic frequencies which are comparatively low in sensitivity; library preps that can artificially increase coverage of some areas over others; and bioinformatically-challenging repetitive sequences. The disclosed non-amplification, long range sequencing can have both sequence and phasing information in the same data and will not incur the same artifacts and mis-mapping errors as prior NGS methods, and given that actual DNA molecules are being sequenced, the disclosed methods also provide a direct enumeration of the allelic ratios of mutant to normal alleles without necessarily needing UMIs. In addition, the disclosed methods provide improved bioinformatics support, and the CR1SPR enrichment step can further enrich for the mutation regions of interest.

[0049] Accordingly, disclosed herein is a novel assay for the interrogation of prognostic genetic markers in leukemia, including AML, using rapid CRISPR-enrichment based single molecule long range sequencing to overcome the limitations of prior leukemia diagnostic and treatment methods, including by improving upon current laboratory standards. The ability to examine non-amplified single molecules of DNA enables the elucidation of the heterogeneity of mutations and fusion gene breakpoints through sequencing in acute leukemia (AL) with higher accuracy (as compared to amplicon-based testing), which provides a deeper understanding into the biology of leukemia. Longsequencing reads can also provide novel insight into phasing for specific genetic mutations like FLT3. Specific novel aspects of the disclosed assays include: I . targets a specific set of AL related genes with rapid, robust multiplexed CRISPR enrichment library that includes a uniquely designed guide RNAs that targets these regions of interest to allow for sequencing of long nucleic acid molecules customizable to target genes of interest, and 2. applies this chemistry for use in acute leukemia with real-time long read sequencing strategies such as nanopore or long-read sequencing systems, e.g., as can be provided by PacBio®<

[0050] The disclosed approaches provide novel chemistry and real-time technologies for fast library preparation in a robust enrichment and provide tremendous commercial advantages in: 1. Accuracy: The clinical utility of a rapid, non-amplified, multiplexed sequencing assay provides more accurate molecular data and subsequently a faster, more efficient workflow between initial diagnosis and initiation of a therapeutic regimen that is tailored to the patient both prognostically and targeted biomarker-specific relevant. Additionally, a non-amplified assay enables more accurate estimation of tumor burden in a sample since any mutations or fusions genes are now calculated based off of unique DNA molecules directly sequenced. 2. Precision: The disclosed assay detects the specific fusion gene breakpoint which enables the attractive concept of “precision diagnostics” and “measurable residual disease” detection, to help better understand the underlying mechanism of the translocation. The identification of specific genetic sequence of a fusion breakpoint such as in the case of CML, provides a highly sensitive and personalized marker for MRD detection in patients that impact management decisions such as switching Tyrosine Kinase Inhibitors (TKI) or cessation of TKI therapy. A nonamplified assay enables more accurate estimate of tumor burden in the sample since any mutations or fusions genes are now calculated based of unique DNA molecules that were sequenced. 3. Innovation: An innovation of this disclosure includes unique guide designs with optimized chemistries and user-accessible bioinformatics. This new chemistry allows for the examination of fusion genes and mutations in a non-amplified, long-range manner. This approach scrutinizes any breakpoint heterogeneity, mutations in the fusion genes, and phasing locations of mutations that can lead to disease resistance. The disclosed approachesenable the interrogation of multiplexed genes simultaneously through sequencing for molecular-level detection.

[0051] In various implementations, long read real-time sequencing technology (LRRTS) can enhance the understanding of the pathobiology of genomic alterations and mutations in AML, because it allows for sequencing of long unbroken fragments of DNA. Using directional CRISPR / Cas9 cuts, the disclosed methods can enrich for specific genomic regions that can be sequenced on the nanopore platform. The added benefit of long-range sequencing allows for better fusion detection, a hallmark of many acute leukemias, through better mapping performance. With the combination of CRISPR and long read sequencing technologies, the disclosed methods can map the specific genomic breakpoint for difficult regions in a more efficient and cost-effective assay.

[0052] While at least some previous efforts have related to real-time sequencing assays that are PCR amplification-based, these approaches analyzed short reads, reducing the ability of these approaches to detected aberrations. Long range non-amplified sequencing has previously been performed on a single patient sample and this approach demonstrated the ability to obtain a specific breakpoint in 28.5 hours, however, these approaches have not utilized any non-amplificati on-based modality or any CRISPR enrichment protocol that can lead to faster turnaround times when combined with real time bioinformatics analysis. Furthermore, these prior efforts have not developed any assay to detect the specific AL hotspot gene regions or the specific guide RNA set described herein to target prognostic and therapeutically important variants and genomic aberrations. As described herein, by coupling long read sequencing technology with real time bioinformatics analysis, evidence for mutations of interest can be accumulated as the sequencing occurs. Standard short read NGS approaches leverage complex bioinformatics algorithms to reconstruct longer consensus sequencing in order to overcome the challenge of identifying variable translocation breakpoints. By coupling real time bioinformatics with LRRTS like Nanopore, chimeric reads that span multiple chromosomes over large ranges (like BCR-ABL spanning a region of > 150kb) can be readily identified by analyzing the sequences of each unique molecule on the fly, as described herein. The disclosed real time pipeline provides a cumulative coverage map of the target regions, and when sufficient statistical evidence is reached based on the unique reads processed to support the existenceor absence of mutations, the pipeline can trigger an end of run to save analysis time and sequencing resources.

[0053] The disclosure provides, among other things, approaches for analysis of a set of targets (see, e.g:, Table 5) together with use of disclosed example CRISPR guides to cut d genomic DNA and enrich for DNA re Ogions of interest. In addition, 7 further developments with guide design can be implemented for all targets, including when multiplexed. The disclosure provides: a new7series of optimized CRISPR guides and results from testing the guides for efficiency per target; matched pools of guides with high and similar levels of efficiency; and results from multiplexing experiments with mixing the guide RNAs for 5 targets with mutations (i.e., FLT3, NPM1, CEBPA, IDH, JAK2) to ensure no drop-in guide efficiency occurs and to establish an expected baseline. For multiplex guide efficiency, the mutation pool can be used as a baseline, as multiple fusion genes can be unexpected to occur in the same patient sample. The disclosure also provides results from a series of experiments to detect the fusion gene in combination with the multiplexed mutation pool to ensure detection of structural variants and smaller variants can occur at the same efficiency. This can be performed by adding t(15, 17), followed by t(8;21 ), followed by inv!6, then t(9;22), and NUP98-NSD1, last, in at least some embodiments. The disclosed approaches for data analysis and bioinformatics can be performed based on the disclosure and implemented for detecting a di verse set of small and large variant types (including structural variants) at various limits of detection, and for developing and validating clinical next generation sequencing assays for hematopathology (e.g:, myeloid malignancies mutation panels). One can also develop scalable and portable bioinformatics pipelines using workflow management systems like Snakemake and containerization technology, e.g.. Docker. One can develop an initial QC / QA pipeline coupled with a prototype variant calling pipeline to detect small mutations and fusion breakpoints.

[0054] In embodiments, multiple assays with multiplexed target mutations and a fusion gene in single or smaller subsets can be implemented.

[0055] The disclosure provides a new amplification-free enrichment protocol with long-range single molecule DNA sequencing that is configured to detect the genomic breakpoint for several common fusion genes in AML. Selection of the targets for this assaywas carefully carried out, with consideration given to current standard of care and knowledge of prognostic markers, as well as specific markers with targeted therapy. A CRISPR-based PCR-free enrichment protocol is followed and products are sequenced with nanopore sequencers. Using self-designed guides from the CHOP-CHOP application (Labun, K., Montague, T. G., Krause, M., Torres Cleuren, Y. N., Tjeldnes, H., & Valen, E. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Research (2019).), this disclosure details the creation and testing of individual assays for five translocations (t( 15 ; 17), t(8;21 ), inv( 16), t(9;22), and t(5 ; 11 )), and two genes (FLT3 and CEBPA) that are hotspots for prognostic mutations. The disclosure tested 4-6 probes / target, with further changes envisioned for management of efficiency and multiplexing.

[0056] The disclosure evaluates nine verified runs, wherein mutations and fusion genes were confirmed with the disclosed approach. The BCR-ABL breakpoint of three CML cell lines was confirmed with published genomic breakpoints (K562, KU812, and KCL22) and 2 CML patients. Additionally, the PML-RARA fusion was confirmed for the NB4 cell line and one APL patients. In the shortest run, within 2 hours, with 4,718 reads with a good quality score (median Phred score of 12.97) and a 293-fold enrichment, BCR- ABL 1 was confirmed with a portable sequencer that costs USD$900. In contrast, for a multiplexed reaction with a Flongle®1flow cell (the USDS90 sequencer), the disclosure describes attainment of over 100,000 reads in 15 hours, with a less-than-optimal quality' Phred score of 9.9 and 74-fold enrichment of the target region confirming BCR-ABL I, CEBPa, and FLT3.

[0057] In embodiments, multiple CRISPR-guides can be used to cover variants and capture genomic breakpoints, with at least some redundancy to maximize target coverage efficiency. For example, one can utilize 7 probes to cover BCR-ABL as the breakpoint in this translocation can occur within a very large region (> 150 Kb), and 6 probes for PML- RARA to cover 2 common variant fusions. Further changes to the approach can allow to reduce the number of guides needed, thus bringing the potential for multiplex targets to 30-35 (for a theoretical maximum number of probes of 100).

[0058] In embodiments, methods include enrichment with CRISPR-Cas9 processes and long real time sequencing for rapid AML- prognostication and diagnosis. With thedisclosed approaches, one can multiplex two mutations and a fusion gene together, complete library preparation in less than 4 hours, and obtain enough sequencing data in 12 hours to support detection for mutations of interest. This timeframe enables faster diagnosis and decreases the time to treatment. In addition, the disclosed CRISPR guides are effective for enriching for DNA regions of interest for sequencing on a long-range sequencing platform. The disclosure provides a sequence alignment and QC / QA pipeline that can be used to assess the efficiency of the CRISPR guides, which can be used as a clinical assay. The disclosure also envisions a variant calling pipeline to automatically detect both small and large variant classes for target clinical utility. Results from use of a set of CRISPR guides of the disclosure demonstrate the overall feasibility of the process.

[0059] The methods, compounds, compositions, kits, and devices of the disclosure enable access to rapid, affordable, and accurate clinical assays for value-based healthcare for acute leukemia patients. The disclosed assays support effective detection for recurrence of disease through repeat longitudinal tracking that is at a significantly lower price point for the patient and that will lead to higher compliance over time.

[0060] The disclosure provides an accessible bioinformatics pipeline that, is compatible for use with Nanopore sequencing, and which can produce FAST5 files which can be analyzed and converted to FASTQ sequencing files by any of a number of software programs, including but not limited to MinKNOW™, among others.

[0061] In embodiments, bioinformatics software tools of the disclosure utilize one or more user-friendly interfaces to help users and clinicians access the bioinformatics report, generated from the rapid analysis of the real-time sequencing data, and can include a binary (yes or no) call for each mutation or fusion in the panel, along with supporting variant metrics.

[0062] Table 6 lists several example targets and CRISPR guideRNAs. The table includes the significance of the target, including if there are prognostic and treatment implications, the incidence they are seen in AML, and the references specific to that marker. General prognostic information for selection of these targets are available in Dohner H, et al. Diagnosis and management, of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182 / blood-2016-08-733196. Epub 2016 Nov 28. PMID: 27895058; PMCID:PMC5291965 and Papaemmanuil E, el al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056 / NEJMoal516192. PMID: 27276561; PMCID: PMC4979995, the contents of which are incorporated by reference herein.

[0063] Current classification of myeloid malignancies is largely based on the molecular and genetic aberrations present in the genome. Recurrent gene rearrangements are present in 30-40 % of acute myeloid leukemias (AML), and well described driver mutations that in some cases suffice to diagnose leukemia (t(15; 17), t(8;21 ), and inv(16)) even when the blast percentage is below 20%. In most cases the resulting fusion genes confer certain clinical and biological characteristics. These recurrent fusions often serve as drivers of leukemogenesis and thus drive prognosis stratification and are key to inform treatment decisions. This is relevant when therapies that target a specific fusion driver are available. In Chronic myelogenous leukemia (CAIL), the pathognomonic Philadelphia chromosome resulting in a BCR-ABL1 fusion, indicates the patients can be treated with tyrosine kinase inhibitors (TKIs) targeting ABL1 overexpression and thus altering patient survival that now approaches the survival of general population. Acute promyelocytic leukemia (APL) represents another hematologic malignancy where identification of the promyelocytic leukemia- retinoic acid receptor alpha (PML-RARA) fusion confirms not only the diagnosis but also indicates that patient will likely respond to treatment with all- trans retinoic acid (ATRA) therapy, which induces maturation in blasts and promyelocytes in most patients, providing a nontoxic and highly effective treatment. 90 % long term survival rates can be achieved even in high-risk patients using regimens combining ATRA with anthracyclines and / or arsenic trioxide therapy.

[0064] Fusion genes can be detected through several techniques that include cytogenetics techniques such as fluorescence in situ hybridization (FISH), and molecular testing such as polymerase chain reaction (PCR) and next generation sequencing (NGS). Despite novel techniques becoming available, the ones listed above remain the gold standard. Clinical molecular assays for BCR-ABL1 and PML-RARA primarily target RNA transcripts by RT-PCR because of the greater abundance of fusion gene transcripts compared to the DNA copies per cell and the patient-unique genomic fusion sequences in CML that thwart the use of a generic BCR-ABL 1 genomic test. NGS by itself is inadequateto cover this variety of aberrations in myeloid neoplasms that require different assays in molecular and cytogenetics labs to confirm fusion genes, single nucleotide variants, varying sizes of insertions and deletions, and copy number variations needed complete the diagnostic molecular picture, because NGS does not generate long reads that are sufficient to overlap sequence from DNA fragments it has limitations when detecting large genomic aberrations.

[0065] The advancement of long-range sequencing technologies has enabled the sequencing of unbroken single DNA or RNA molecules up to tens to hundreds of kb long. Ongoing improvements in nanopore sequencing accuracy have reduced error rates to less than 5 %, although error rates are still higher than platforms such as Illumina® and Ion Torrent®. However, as sequencing becomes increasingly accurate, this technology has already made an impact on the understanding of the pathobiology of various diseases. As described herein, the addition of CRISPR / Cas9 for targeted enrichment concentrates the regions of interests prior to sequencing by nanopore, without requiring amplification steps, thus optimizing for sequencing time and efficiency. Additionally, the portability' and affordability of the nanopore sequencer Mi nION™ can impact the clinical field.

[0066] Herein, the feasibility of an amplification-free CRISPR / Cas9 targeted enrichment sequencing protocol on a nanopore MinI0NEMto detect fusions and other mutations relevant in the diagnosis and classification of AMLs is described. The disclosed assays were designed to capture varied breakpoints of CML and APL, as well as fusion genes resulting from inv(16) and t(4; 11). Simultaneous interrogation of these targets allows for a rapid characterization of AMLs combining data that up to now required multiple different techniques, and provides relevant information promptly.

[0067] The present disclosure deviates from prior, standard fusion detection molecular assays that use RNA as input materials and captures hybrid transcripts. Long read sequencing technologies, like the nanopore described herein, allows sequencing of unamplified, long unbroken fragments of DNA. Long reads hold advantages over short reads for the detection of gene fusions, as they are more likely to span a breakpoint. A benefit of sequencing DNA for the detection of fusion breakpoints is showcased in CML where MRD can be detected by DNA PCR of the BCR-ABL1 fusion, even if undetectable by quantitative RT-PCR, suggesting higher sensitivity for DNA assay. DNA is more stablethan RNA and it is present in constant numbers in cells, but the unique genomic breakpoints sequence that identifies individual patients requires patient-specific breakpoint characterization. Because of the extensive region there, the breakpoint can lie in ABL1, comprising about 150 Kb, this is an arduous endeavor when approached with conventional methods usually involving multiple primer sets and Sanger Sequencing. The sensitivity of DNA-based qPCR once the breakpoint is known can be as low as 10’7. Additionally, DNA is a beneficial template when fresh tissue is unavailable, i.e., when tissue samples are formalin fixed and paraffin embedded (FFPE). When patients are on TKI therapy and thus suppressing RNA transcriptions of the fusion gene, DNA and RNA concentrations of the fusion genes are roughly similar, and in these instances targeting DNA can provide a more robust and reproducible assay. The method described herein makes the genomic characterization of BCR-ABL1 breakpoint in individual patients quick and simple, simplifying the path to patient specific primers for monitoring MRD. Furthermore, uncovering the specific sequence of the breakpoint in BCR-ABLI may shed light on the mechanism leading to this fusion.

[0068] The example CRISPR enrichment protocol disclosed herein is based on the CRISRP-Cas9 system which allows multiplexing by pooling multiple guide RNAs. The regions targeted are where the translocations are typically seen in each of the 2 genes involved in each fusion. Under this non-amplifi cation protocol, total library preparation time from sample to sequencer loading is within 3 hours, and generally the sequencer can be allowed to run at least overnight (12-18 hours). Building from previous experience with Anchored multiplex PCR data where UMI distills the sample down to unique RNA molecules in the input sample, together with the consideration of the increased specificity inherent to mapping long reads, the 3 unique hybrid reads can suffice to confirm a fusion. Three sequences were detected after 3 hours of sequencing in most primary specimens. With real time analysis enabled, this enables diagnosis 8 hours after reception of specimen. With current sequential analysis with the flow work described herein, a diagnostic result with 3 fusion supporting reads is possible after approximately 18 hours (the primary specimen with longest sequencing time to 3 fusion reads reached them after a few minutes before 11 hours). The disclosed series include 5 specimens sequenced on a Flongle^ device, a platform with significant lower cost than the regular flow cells, but also withlower sequencing capabilities (guaranteed pore count of 60 instead of 800 by the manufacturer, and sequencing live of 24 h instead of 72 h). Three fusion reads were reached in 4 / 5 specimens. The sequencing quality obtained from the Flongle® is significantly lower than that obtained from the Flow Cells, as reflected by the median Phred score (9.2 in the Flongles®, and 11.9 in the Flow Cells); however, fusions were detected in all samples with enough disease. The cost of the Flongles® is 1 / 10 that of the regular flow cells, and configuration of the assay for this type of platform can mean a fast and very affordable molecular diagnostic method for acute leukemias.

[0069] Shorter run times predicted than the ones used in the disclosed experiments could demonstrate the on-target fusion reads. Flongle® Phred quality is lower in Flongles®vs minions on average and therefore changes to the setting of the basecaller are needed to see the reads.

[0070] With the disclosed workflow, genomic DNA can be extracted from patient specimens within 2 hours, and library preparation completed with the CAS-9-CRISPR chemistry within 2 hours and loaded onto a nanopore sequencing cell. As nanopore begins sequencing almost immediately, and when paired with the disclosed GPU-enabled data analytic pipeline in the Bwb, the disclosed approached significantly help to interpret and reliably identify fusion reads within 5000 seconds or less than 2 hours. The disclosed approaches therefore enable same day data review and reporting. This means the time from sample acquisition to fusion confirmation could be performed in less than 8 hours, providing great potential for rapid diagnostics for fusion genes, which is critically important for patients with acute leukemia to allow for guided selection of the most appropriate treatments.

[0071] Advantages of long-range sequencing over prior assays for clinical diagnostic include, but are not necessarily limited to, the speed and relatively low complexity of the assay when compared to cytogenetics and NGS platforms with targeted panels. While long-range sequencing results can have a turnaround time of 48 hours, Karyotype TAT is longer, and targeted NGS panels typically require about 2 weeks from start of processing to result report. Long range CRISPR enrichment can include targeting specific genes, but it can also allow for the detection of novel fusion partners. Additionally, it is a useful technique to detect fusions that do not translate in a fusion protein (fusionsinvolving promoters, like IGH-Myc in Burkitt’s lymphomas). Furthermore, the disclosed platform uncovers genomic fusion sequences that can be applied to personalized medicine for residual disease or clonal monitoring. Further studies with primary specimens can be implemented for the development of this platform clinical assay, to study the lower limit of detection and to determine the minimum reads on target that can be used for interpretations.

[0072] In an aspect, the disclosure provides a method of treating a subject diagnosed with, or suspected of having, at least one form of leukemia. Such a treatment method comprises, generally, identifying one or more characteristics of at least one leukemia gene mutation, point mutation, variant, aberration, alteration, or fusion, and treating the leukemia based at least in part on the one or more characteristics identified. Such a method comprises contacting a DNA molecule that comprises a leukemia gene mutation with an endonuclease-guide RNA complex to generate a long-chain DNA molecule. The long-chain DNA molecule comprises the leukemia gene mutation. The method further comprises sequencing, without any molecular amplification or copying of the long-chain DNA molecule, the long-chain DNA molecule with a long-range sequencing method to produce a sequence read. The method comprises computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read. The characteristic corresponds to the leukemia, in particular, an identity of the leukemia or an expected outcome of a given treatment of the leukemia. The method further comprises administering a leukemia treatment to the subject based on the characteristic.

[0073] In another aspect, the disclosure provides a method of diagnosing a subject with a leukemia. The method comprises contacting the DNA molecule that, comprises the leukemia gene mutation, variant, aberration, alteration, or fusion with the endonucleaseguide RNA complex to generate the long-chain DNA molecule that comprises the leukemia gene mutation, point mutation, variant, aberration, alteration, or fusion, and sequencing, without any molecular amplification or copying of the long-chain DNA molecule, the long- chain DNA molecule with the long-range sequencing method to produce the sequence read. The method comprises computing, with the computational method, the characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read. Since thecharacteristic corresponds to the leukemia, it can be used for a diagnosis. As such, the method comprises diagnosing the subject with the leukemia, based at least in part on the characteristic. In at least some embodiments, such a method can be used for determining a prognosis of the leukemia, for example, as can be performed during a course of treatment or after an initial diagnosis.

[0074] Any leukemia can be treated, diagnosed, and prognosed using one or more aspects of the disclosure. In at least some embodiments, the leukemia comprises acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (API .). myeloproliferative neoplasm (MPN), mixed-lineage leukemia (MLL), or any combination thereof. In certain implementations, the leukemia comprises AMI,.

[0075] In embodiments, the characteristic of the leukemia gene mutation comprises a genetic mutation, a deletion, an insertion, a substitution, a frameshift, a breakage, a fusion, a genetic phase change, or any combination thereof. In at least some embodiments, the leukemia gene mutation comprises: the leukemia gene mutation comprises: an ASXL transcriptional regulator 1 (ASXL.1) mutation, an fins related receptor tyrosine kinase 3 (FLT3) mutation, a CCAAT enhancer binding protein alpha (CEBPA) mutation, a nucleophosmin 1 (NPM1) mutation, an isocitrate dehydrogenase (NADP(+)) 1 / 2 (IDH1 / 2) mutation, a calreticulin (CAL.R) mutation, a KIT proto-oncogene receptor tyrosine kinase (KIT) mutation, a Janus kinase 2 (JAK2) mutation, a tumor protein P53 (TP53) mutation, a t(15;l 7)(q24.1;q21.2) PML-retinoic acid receptor alpha (RARA) translocation that, forms a fusion gene, a t(8;21 )(q22;q22. 1) RUNX family transcription factor 1 (RUNX1)- RUNX1 partner transcriptional co-repressor 1 (RUNX1T1) translocation that forms a fusion gene, a translocation between core-binding factor subunit beta (CBFB)-myosin heavy chain 11 (MYH11) (invl6) that forms a fusion gene, a t(6;9) translocation between genes DEK protooncogene (DEK)-nucleoporin 214 (NUP214) that forms a fusion gene, a t(l;22) translocation between genes DEK protooncogene (DEK) and nucleoporin 214 (NUP214) that forms a fusion gene, a translocation t(9;22)(q34;ql 1) between breakpoint cluster region (BCR) and Ableson murine leukemia viral oncogene homolog 1 (ABL1) that results in a fusion gene, a non-receptor tyrosine kinase (ABL1) mutation, a translocation between nucleoporin 98 and 96 precursor (NUP98) to nuclear receptor binding SET domain protein1 (NSD 1 ) that results in a fusion gene, an MIX rearrangement that, results in a fusion gene, or arty combination thereof. In embodiments, the leukemia gene mutation comprises: the PML-RARA mutation, the ABL1 mutation, the MLL mutation, a fusion that involves at least one gene rearrangement of one or more of these or other genes, or any combination thereof. In embodiments, a plurality of leukemia gene mutations, deletions, insertions, substitutions, frameshifts, breakages, fusions, genetic phase changes, or any combination thereof can exist.

[0076] In embodiments, the endonuclease-guide RNA complex comprises a guide RNA (gRNA) comprising a sequence selected from SEQ ID NOs:1-70. In embodiments, the long-chain DNA molecule comprises a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71 -140.

[0077] In embodiments, the long-chain DNA molecule is not amplified by any polymerase chain reaction (PCR) technique or any isothermal DNA amplification technique. By omitting an amplification step from the assay, the methods of the disclosure can be performed even in the absence of PCR and other laboratory equipment, thereby reducing costs and technical expertise requirements. This and other improvements as described herein significantly increase the accessibility of the disclosed assays to larger populations and enable these assays to be reliably performed even in remote areas or villages with little or no access to electric power.

[0078] In embodiments, one or more leukemia treatment compositions is administered to the subject for treatment of the leukemia. In embodiments, the one or more leukemia treatment compositions comprises an FLT3 inhibitor, an 11)1 11 inhibitor, an IDH2 inhibitor, a Jak2 inhibitor, an HD AC inhibitor, all-transretinoic acid (ATRA), an anti-CD33 targeted therapeutic compound, a tyrosine kinase inhibitor, a chemotherapeutic compound, a DOT IL inhibitor, or any combination thereof. In embodiments, the FLT3 inhibitor comprises midostaurin, gilteritinib, or both. In embodiments, the IDH1 inhibitor comprises ivosidenib. In embodiments, the IDH2 inhibitor comprises enasidenib. In embodiments, the one or more leukemia treatment compositions comprises the Jak2 inhibitor and the HDAC inhibitor. In embodiments, the one or more leukemia treatment compositions comprises the ATRA and the anti-CD33 targeted therapeutic compound. In embodiments,the tyrosine kinase inhibitor comprises dasatinib, imatinib, midostaurin, or any combination thereof.

[0079] In an aspect, the disclosure provides circuitry configured for performance of a method, the method comprising: downloading, from a cloud computing device, genomic data that is relevant to leukemia; electronically storing raw sequence data to a n on-transitory computer-readable storage medium as n on-transitory data; basecalling the non-transitory data that comprises the raw sequence data to produce nucleotide base data that correspond to nucleotide bases of a sequenced long-chain DNA molecule; indexing and aligning the nucleotide base data with alignment data and gene definition data for an alignment; computing, from the alignment, one or more leukemia gene aberrations of the sequenced long-chain DNA molecule, wherein the one or more leukemia gene aberrations is inclusive of leukemia gene aberrations that are proximal and distal to a leukemia gene breakpoint; and depicting, with an electronic display, the alignment and the one or more leukemia gene aberrations of the sequenced long-chain DNA molecule.

[0080] In embodiments, at least the computing of the one or more leukemia gene aberrations is performed by a Biodepot Fusion Finder (BFF) software that configures the circuitry to compute fusion enrichment and on-target enrichment statistics for the computing of the one or more leukemia gene aberrations.

[0081] In an aspect, the disclosure provides one or more computational devices or systems comprising the circuitry.

[0082] In an aspect, the disclosure provides a guide RNA comprising a sequence as set forth in any of SEQ ID NOs:l-70. In embodiments, the guide RNA is configured to bind a target sequence comprising a sequence as set forth in any of SEQ ID NOs:71-140.

[0083] In an aspect, the disclosure provides an endonuclease-guide RNA complex comprising a guide RNA, as well as a plurality of endonuclease-guide RNA complexes, wherein each endonuclease-guide RNA complex comprises a guide RNA that targets DNA that comprises a leukemia gene mutation.

[0084] In an aspect, the disclosure provides a composition comprising an endonuclease-guide RNA complex. In an aspect, the disclosure provides a kit comprising such a composition and an instructional material configured to instruct a user for a use of the kit in performance of a method.

[0085] In an aspect, the disclosure provides a probe for detecting a leukemia gene mutation, the probe comprising a sequence as set forth in any of SEQ ID NOs: 1-70, wherein the probe binds to a target sequence comprising a sequence as set forth in any of SEQ ID NOs:7L14().EXAMPLES

[0086] Example 1. Rapid detection of myeloid neoplasm fusions using Single Molecule Long-Read Sequencing

[0087] Abstract

[0088] Recurrent gene fusions are common drivers of disease pathophysiology in leukemias. Identifying these structural variants helps stratify disease by risk and assists with therapy choice. Precise molecular diagnosis in low-and-middle-income countries (LMICs) is challenging given the complexity of assays, trained technical support, and the availability of reliable electricity. Current fusion detection methods require a long turnaround time (7—10 days) or advance knowledge of the genes involved in the fusions. Recent technological developments have made sequencing more accessible, potentially making molecular diagnosis accessible to remote areas and low-income settings, however, there is still a significant unmet need for low-cost, high-accuracy testing for LMIC and other scenarios.

[0089] This example provides a long-read sequencing DNA assay, designed with CRISPR guides to select and enrich for recurrent leukemia fusion genes, that does not need a priori knowledge of the abnormality present. By applying rapid sequencing technology based on nanopores, long pieces of genomic DNA were sequenced and fusion genes successfully detected in cell lines and primary / specimens (e.g., BCR::ABLI, PML::RARA, CBFB::MYH11, KMT2A::AF4, RUNX1::RUNXJT4) using cloud-based bioinformatics workflows with novel custom fusion finder software. Fusion genes were detected in 100% of cell lines with the expected breakpoints and the presence or absence of a recurrent fusion gene w'as confirmed in 12 of 14 patient cases. With the disclosed assay and cloud-based bioinforrnatics workflow', these assays and analyses can be performed in under 8 hours. At least the platform’s portability, potential for adaptation to lower-cost devices, andintegrated cloud analysis make this assay able to be placed in settings like LMIC to bridge the need of bedside rapid molecular diagnostics for leukemias.

[0090] Introduction

[0091] Low-and middle-income countries (LMICs) suffer the heaviest burden of cancer deaths. Scarce pathology services that result in incomplete, inappropriate, or del ayed diagnoses are one of the causes of higher morbidity and mortality rates. A slow or incorrect diagnosis can result in disease progression with worsening prognosis, or incorrect treatment decisions. A systematic review showed that earlier testing after the start of symptoms is associated with lower-stage disease and improved survival benefits for breast, colorectal, head and neck, prostate cancers, and melanoma. In 2017, only 1 / 4 of low- income countries reported having readily available access to pathology services. In response, the WHO published a guide to early cancer diagnosis emphasizing the importance of early diagnosis to include access to disease evaluation to guide subsequent treatment.

[0092] The current classification of myeloid malignancies is largely based on molecular and genetic aberrations. Recurrent gene rearrangements are present in 30-40% of acute myeloid leukemia (AML), and well -described driver fusions sometimes suffice to diagnose leukemias (for example, PMLzRARA, or RUNX1::RUNX1T1 among others). These fusion genes confer specific clinical and biological characteristics as drivers of leukemogenesis that can assist in prognosis stratification and inform treatment decisions. Detection of diagnostic fusions can be especially relevant in developing countries to guide the use of resources as they have several novel target therapies available, since they are included in the WHO list of essential medicines. Examples include tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CAIL) that block BCRv ABLl kinase activity and differentiation therapy with all -trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) targeting the (PMLzRARA) fusion.

[0093] Typically, fusion genes are detected by fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) assays, or next-generation sequencing (NGS). NGS is an attractive technology because it should be able to detect a variety of genetic mutations found in leukemia, including fusions, insertions, deletions, and point mutations in oncogenic genes. However, conventional NGS has technical hurdles (short sequencingreads, introduction of false positive errors due to library preparation) and hardware issues (expensive machines, complicated bioinformatics). These issues make NGS hard to employ readily in LMIC settings.

[0094] The advancement of long-read sequencing technologies has enabled the sequencing of continuous single DNA or RNA molecules up to tens to hundreds of kilobases (kb) long. Ongoing improvements in Nanopore® sequencing accuracy have reduced error rates to less than 5% but remain higher than those for Illumina® and Ion Torrent11-1platforms, which are used frequently in clinical laboratories. Long-read sequencing has made an impact on the understanding of the pathobiology of various diseases, and its impact should increase as the sequencing quality improves and becomes more accurate. As described herein, addition of CRISPR— Cas9 for targeted enrichment concentrates the regions of interest prior to sequencing by Nanopore® without requiring amplification steps, thus optimizing sequencing time and efficiency. In addition, the portability and affordability of the Nanopore® sequencer Min-ION® and Flongle® can provide the ability to improve the clinical field, especially in the LMIC setting. However, a limitation of these approaches has included the lack of analytical software featuring standardized parameters to aid in translation into clinical diagnostics. Implementing such a portable platform with reduced cost and cloud-based on-demand analysis workflow in developing countries would enable testing centers to provide sequencing without investing in a computing or bioinformatics infrastructure, thus bridging the gap between diagnosis and tailored treatment administration.

[0095] This example describes an amplification-free CRISPR-Cas9 targeted enrichment sequencing protocol using Nanopore® MinlON® flow cell and Flongles® to detect fusions relevant to the diagnosis and classification of CML and AMLs. The ONT (Oxford Nanopore Technologies®) Flongle® is an adaptor for the MinlON® that provides cost-effective (e.g., -USD $90 per MinlON® flow cell) real-time sequencing for smaller assays of limited target genes. These assays were designed to capture various breakpoints of CML and APL, as well as fusion genes resulting from inv(16) (CBFB::MYH11) and t(4; 11)(KMT2A:: AFF1). Simultaneous interrogation of these targets can be a step to rapid characterization of AMLs in a single assay. This approach combines data that previously required multiple different techniques; as described herein, it provides relevant informationpromptly. In addition to this amplification-free CRISPR-Cas9 nanopore assay, extended a previously developed cloud-based Nanopore® data analysis pipeline (Reddy S, et al, A graphical, interactive and GPU-enabled workflow to process long-read sequencing data. BMC Genomics. 2021;22(l):626.) to include fusion detection and develop a custom breakpoint detection tool (FIGs 1A and IB). Using the disclosed assay and custom breakpoint finder, it is shown that one can reliably detect and confinn fusion breakpoints in 80% of the specimens in under 3 hours total time, including sequencing and data analysis.

[0096] Materials and methods

[0097] Cells lines and patient samples

[0098] The assay was developed using 7 cell lines: three with the BCR::ABL1 fusion (K562, KU8I2, and KCL22), and NB4, MV4;11, ME-1, and Kasumi, that bear the PML::RARA, KMT2A::AF4, MYH11 ::CBFB, and RUNX1::RUNX1T1 fusions respectively. Residual mononuclear cells from primary specimens ( six specimens from five patients with CML six, specimens from five patients with suspected APL, and two acute myeloid leukemia, not acute promyelocytic leukemia) were isolated using Ficoll® reagent (Millipore-Sigma) and banked in liquid nitrogen until the time of the experiment. All specimens had been initially tested in a CLIA certified laboratory' according to standard clinical protocols. (Yeung C, et al.. Mutational profiling in acute lymphoblastic leukemia by RNA sequencing and chromosomal genomic array testing. Cancer Med. 2021;10(16):5629-42). IRB coverage was obtained for use of residual laboratory' samples. Patient samples were de-identified to the Nanopore testing lab, and cytogenetic or molecular results were confirmed after nanopore results were rendered. Characteristics and demographics of specimens and patients are listed in Table 1.

[0099] Library' preparation and sequencing assay

[0100] For the cell lines and 11 / 14 patient specimens, the DNA was extracted with PureGene® (Qiagen®, Germantown, MD, USA) following the standard protocol. Special caution, including the use of wide-bore pipette tips and moderate centrifuge spin velocity, was exercised to minimize fragmenting DNA strands. Two DNA specimens were extracted with AllPrep® DNA / RNA Kit (Qiagen®, Germantown, MD, USA) and one with QiAgen X-tractor® with Reagent Pack DX® (Qiagen®, Germantown, MD, LISA). cRNA guideswere designed to direct Cas9 to cut on the genomic proximity of each region involved in the translocations studied. When the target region was large, guides were tiled across the region to maximize coverage. Guides were designed to capture PML: :RARA, BCR: :ABL1 p210, KMT2A::AFF1, and CBFB::MYH11, including different fusion isoforms. Guides were designed using Chopchop (https: / / chopchop.cbu.uib.no / ) with appropriate CRISPR- Cas9 and nanopore enrichment settings as previously described (Sala-Torra O, el al., TTMV::RARA fusion as a recurrent cause of AML with APL characteristics. Blood Adv. 2022.). CRISPR guide RNAs, and any other probe of the disclosure, can include a linker sequence; in this example, the probes included a linker comprising the sequence GUUUUAGAGCUAUGCU (SEQ ID NO: 156).

[0101] Five micrograms of DNA was used as input for each cell line and 2 to 5 micrograms for primary specimens. The average DNA integrity number (DIN) was 9.2 (range: 7.5-9.8). FIGs 1A and IB show a schematic of an example workflow; details of the library prep were as per Sala-Torra O, el al., TTMV-RARA fusion as a recurrent cause of AML with APL characteristics. Blood Adv. 2022. Briefly, with regard to library' preparation, enrichment of target regions was obtained using Oxford Nanopore Technologies’® “Targeted, amplification -free DNA sequencing using CRISPR-Cas9” protocol (Gilpatrick T, et al., Targeted nanopore sequencing with Cas9-guided adapter ligation. Nat Biotechnol. 2020;38(4):433-8). The different guides used in the assay were pooled in equimolar amounts of each guide. Through an initial dephosphorylation step, the 5’ ends of the DNA becomes inaccessible to adapter ligation (Gilpatrick T, et al.. Targeted nanopore sequencing with Cas9-guided adapter ligation. Nat Biotechnol. 2020;38(4):433- 8). Double stranded DNA breaks that excise the region of interest are generated with the directional, target-specific RNA guides complexed with tracrRNA and Cas9 enzyme. The Cas9 complex remains bound to the 5’ end of the guide, and the resulting new DNA ends contain a phosphorylated 5’ end that is available for dA tailing and adapter ligation. All libraries generated in this manner were run on a MinlON® (Oxford Nanopore Technologies®, Oxford, UK) nanopore sequencer using MinlON® flow cells version 9.4 or Flongles®. Modifications for libraries sequenced on the Flongle® were only at the library' loading step, in which the amount of Sequencing Buffer and library' beads (both SQK-LSK109, ONT) are reduced from 35 to 13 and 25.5 to 7.5UL respectively, and 0.5UL of SQT is added. QC parameters tracked for each run are listed in Table 2.

[0102] PCR / Sanger sequencing

[0103] Primers specific to BCR::ABL1 patient breakpoints were designed using Primer3 v. 0.4.0. (Krawetz S MS. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press, p. pp 365-86) in 2 cases. 100 ng of DNA were amplified, the PCR product was run on a 2% gel and Sanger sequenced to confirm the genomic breakpoint.

[0104] In embodiments, data analysis can be performed as described in PCT / US23 / 76915, SYSTEMS AND METHODS FOR DETECTING FUSION GENES FROM SEQUENCING DATA, which is incorporated by reference herein in its entirety.

[0105] Orthogonal confirmation of fusions and breakpoints

[0106] Patient specific BCR::ABL1 breakpoints were confirmed by performing PCR and sanger sequencing in 2 cases. Primers were designed using Primer3 v. 0.4.0. 100 ng of DNA were amplified, the PCR product was run on a 2% agarose gel, and Sanger sequenced to confirm the genomic breakpoint. All other patients were confirmed with clinical karyotype and fluorescent in-situ hybridization data. BCR-ABL cell lines breakpoints were confirmed by published data,

[0107] Biodepot- workflow-builder: Interactive and accessible front end for fusion detection

[0108] A graphical, reproducible, and cloud-enabled fusion detection workflow that includes steps of the analyses, including base calling, alignment, fusion detection, and visualization, is provided (FIGs 1 A and IB). In contrast to the NanoFG workflow (Stangle C, el al. Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing. Nat Comimm. 2020; 11(1):2861), the disclosed platform includes the computationally intensive base calling step and an interactive graphical user interface, and can readily leverage GPUs, and be deployed on the cloud. Thus, analyses using the disclosed systems and methods are fast, and the platform is easily and broadly accessible to users. The Biodepot workflow-builder (Bwb) (Flung LH, et al. Building Containerized Workflow's Using the BioDepot-Workflow-Builder. Cell Syst. 2019;9(5):508-14 e3) platform is extended and improved by way of this disclosure;each computational task (module) is represented by a graphical widget that calls a software container in the back end (FIG. IB). Software containers like Docker can include all software dependencies and libraries to execute the code. A Bwb workflow (Reddy S, el al., A graphical, interactive and GPU-enabled workflow to process long-read sequencing data. BMC Genomics. 2021;22(l):626) is contemplated to support the processing of Nanopore data, that can include the use of base callers Guppy (Wick RR, el al.. Performance of neural network basecalling tools for Oxford Nanopore sequencing. Genome Biol. 2019;20(l): 129) and Bonito, (Id} version 6.4.6 using the r9.4.1 hac model, alignment using minimap2 and visualization of results using the Integrative Genomics Viewer (IGV) and GRCh37 hg! 9 as the reference genome. QC can be performed using PycoQC (Leger AL, T. pycoQC, interactive quality control for Oxford Nanopore Sequencing. Journal of Open Source Software. 2019;4(34):1236). Guppy can be used as the base caller. Minimap2 (Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34(18):3094-100) can be used as the aligner and variant caller. Fusions can be visualized on IGV (Robinson JT, et al. Integrative genomics viewer. Nat Biotechnol. 2011,29(1): 24-6) and confirmed on Blast.. In addition, previous efforts are improved upon by the present example, which adds support, for fusion detection, including LongGF (Liu Q, et al., LongGF: computational algorithm and software tool for fast and accurate detection of gene fusions by long-read transcriptome sequencing. BMC Genomics. 2020;21(Suppl 11) 1793) and a custom software of this disclosure, termed “Biodepot Fusion Finder” (BFF).

[0109] Bioinformatics pipeline for fusion detection: LongGF

[0110] LongGF (Liu Q, etal., LongGF: computational algorithm and software tool for fast and accurate detection of gene fusions by long-read transcriptome sequencing. BMC Genomics. 2020;21(Suppl 11):793) is a software tool for fusion detection configured for the high base calling error rates and alignment errors commonly found in long-read sequencing data. LongGF takes as input, a BAM file containing alignments (e.g., generated by minimap2 in this pipeline) and a GTF file containing the definitions of known genes. The output is a log file with detected gene fusions and their supporting reads. A graphical widget for LongGF in the Bwb can be created. FIGs 2A and IB show examples of comparative workflows with output for LongGF versus BFF.

[0111] Custom fusion detection tool: Biodepot Fusion Finder (BFF)

[0112] Reads that span a fusion gene will align to coordinates in both parts of the fusion and provide a specific breakpoint coordinate. A new software tool, the Biodepot Fusion Finder (BFF), is disclosed herein. This software tool examines alternate alignments for each read and identifies the ones that map to coordinates spanning a set of known breakpoints. This strategy improves upon LongGF by allowing for errors in the alignment near the breakpoint. The Breakpoint Finder identifies fusions not detected by LongGF, which looks for supporting reads where the breakpoints are exactly matched. With reference to BFF, a user can provide a panel of breakpoint coordinates of interest. If no panel is provided, BFF can return candidate fusions that span non-adjacent genomic regions. Incomplete coordinates for breakpoints in the panel are supported, the user does not need to define the exact coordinates, nor do both breakpoints need to be given. BFF can return all the reads that match the breakpoints panel in a text file for further inspection by the user, if desired. BFF can identify the precise breakpoint in each read and also give a count of the number of breakpoints found nearby, in all reads. The user can provide a file containing guide coordinates to obtain additional enrichment metrics. A containerized widget can be developed that can be integrated with the Bwb workflows for processing nanopore data. Using these workflows, one can directly analyze raw nanopore data and obtain lists of candidate fusions.

[0113] Benchmarking experiments

[0114] Empirical experiments were performed to benchmark the sensitivity and runtime to detect fusions reliably. Sequencing metrics, including quality scores and timestamps, were obtained for each sample from the sequencing summary text file, an output of the Guppy base caller. Fusions were detected using BFF and LongGF. BFF also provides specific fusion breakpoints. All samples were combined into a dictionary and separated by patient and cell line data. Plots were constructed for each category of data pertaining to the time to reach three fusions and the number of reads to reach three fusions. Finally, the total number of fusion reads detected for each sample were compared between the BFF and LongGF, as shown at FIGs 2A-2C.

[0115] Enrichment assessment

[0116] Two enrichment metrics were computed by BFF and tracked for each sample. First, the fusion specific enrichment was calculated with the formula [(number of fusion reads) / (mean coverage of the genome)]. Second, the on-target enrichment was calculated with the formula [(number of reads that originate from a guide RNA cut point that includes the region of the breakpoint) / (mean genome coverage)]. Reads originating from a guide RNA cut were distinguished by the guide sequence at the beginning of a read. As initial electrical signal data is generated by DNA passing through the nanopores (reads at the beginning of a strand) is error-prone, which affects base calling and, therefore the alignment of the reads so that the start sequence can often be misaligned. Consequently, the BFF considers base pairs of the sequence near the start (default within 50 bp) of a read that, aligns near the coordinates of a guide RNA cut site to have originated from a guide RNA cut. Specific reads cut by guides can be manually confirmed. The allowed error intervals can be customizable. Samtools vl.13 can be used to sort and convert BAM files and determine the average coverage. Picard Collectl IsMetrics generated the unique base pairs mapped metric for each sample.

[0117] Ethics statement

[0118] All patients’ samples used for this study were obtained through Fred Hutchinson Cancer Center (FHCC) institutional review board protocols either as 1) discarded de-identified patient samples or 2) as consent patients collected into a biorepository. Patients enrolled through 1690 are consented, and patient consents are on file. Samples obtained through 547 and 1837 are considered non-human subjects and waived from the consenting process as they are deidentified materials that are discarded after clinical diagnosis has been rendered.

[0119] Results

[0120] Sample sequencing and enrichment

[0121] Details of the sample sequencing and enrichment metrics are included in Tables 2 and 3. A range of 0.04 Gb- 5.47 Gb (gigabases) of sequencing data were generated for each sample for an average mean coverage of the human genome of 0.32-fold (range: 0.01-1.66). Standard quality metrics were adopted for nanopore workflows and N50, a quality metric where half the reads are above this length (range 4.65kb-32.2kb) and median read length for total reads (range 0.87kb- 9.60kb), were tracked. The percentage of readsaligned ranged from 72-96%. Fusion-specific enrichment was 135—837-fold for ceil lines and 6-509-fold for patient samples. On-target enrichment was 849-5830-fold for cell lines and 535-3007-fold for patient samples.

[0122] Concordance ef fusion detection with clinical results

[0123] Concordance with expected results was 100% for cell lines. The expected fusion in 6 / 6 cell lines was detected (3 BCR:ABL1, 1 PML: RARA, 1 CBFB::MYH1 I, 1 KMT2A::AFF1). Breakpoint sequences detected for BCR::ABL1 cell lines are the same as previously published. The presence or absence of fusions was correctly confirmed in 11 / 14 (78.5%) primary specimens, including both diagnostic and measurable residual disease (MRD) cases with a minimum of 3 reads. However, one case (APL6) showed only two fusion reads and was not counted as confirmed. The three missed cases (CML3, APL1, and APL6 in Tables 1 and 2) were specimens with low disease burden, ~0%, 1%, and <5%. BCR::ABL1 was detected in 5 / 6 cases, PML::RARA was detected in 2 / 6 cases, and KMT2A::MLLT3 and CBFB::MYH11 were detected in 1 / 1 case, each. Orthogonal confirmation of the specific breakpoints was conducted for select patient cases via PCR (FIGs I A and IB) and fusion breakpoints of cell lines were compared to published data (Table 4).

[0124] In three specimens from two patients with suspected APL, PML::RARA was not detected, other findings were observed. Clinical and laboratory-- details are listed in Table 2. For the first patient, two specimens, one bone marrow and one peripheral blood (APLA and APL, 5), yielded no PML::RARA fusion reads. This patient presented with an AML morphologically suggestive of APL and an isochromosome 17q without t(15;17) detected by karyotype. While fusion detection software did not detect a fusion, manual inspection showed an insertion in an intronic region of RARA with TTMV viral genome. Patient APL6 (presented with 22% blasts on flow in a <5% marrow which on unblinding showed a complex karyotype with t(l I;17)(q23;q25), including the KMT2A gene. Two reads with KMT2A::SEPTfN9 fusion were detected in a suboptimal but acceptable run (N50 < 5000bp; on-target enrichment 650.66 fold), confirming the lack of t(15;17) or PML::RARA fusion, but the threshold was below the requisite three reads to confinn the KMT2A: : SEP TIN9 fusion.

[0125] Comparison of fusion detection tools

[0126] A comparison of two bioinformatic workflows using different fusion detection methods, namely LongGF vs. Biodepot Fusion Finder (BFF), was conducted. These two workflows are depicted in FIGs 2A-2C. Additionally, BFF computes the fusion enrichment and on-target enrichment statistics that are summarized in Table 2. In most cell line and primary specimens, LongGF has problems detecting BCR::ABL1 and misses fusion reads that BFF identifies. Using the BFF, the average total sequencing and data processing time to 3 reads with fusions in the cell line experiments was 42.75 minutes (range: 18.87-77.65 min) and 188 minutes in the primary specimens where three reads were detected (range: 32-654 min) (FIGs 3A and 3B, and Table 4). Cell line experiments took an average of 11,711 reads to identify three fusion reads (range: 1,321-43,326 reads) and 10,273 reads in primary specimens (range: 1 ,790-24,999 reads) for confirmation of the fusion calls. BFF provides precise breakpoints in each read in addition to the number of breakpoints found nearby (Table 3). In contrast, LongGF only detects and provides breakpoint coordinates only when there are enough supporting reads with the same breakpoint.

[0127] Comparison of Flongles® and MinlON® flow cells

[0128] In five of the example experiments (2 cell lines, three primary specimens), Flongles® was used; in the other experiments, MinlON® flow cells were used. The performance of the comparatively affordable Flongles® was inferior to the MinlON® flow cells, with lower expected average data output from the Flongles® (based on manufacture expectations of -3GB), the N50 and median read length were smaller in Flongle® reads (21,614 vs. 19,166 and 6058 vs. 5250 respectively), and significantly, the median Phred score for Flongle® reads was lower than that for the MinlON® flow cells (9.2 vs. 11.88). Despite the comparatively worse performance of the Flongles®, fusions were detected in 2 of 2 cell lines, and 2 of the three experiments with primary specimens with at least 8 and 14 reads confirming the fusion, and the specimen without fusion confirmation was CML3 with pancytopenia and low disease burden. Accordingly, in various embodiments, any suitable flow cell can be used, including but not necessarily limited to Flongle® and MinlON® flow cells as described herein by way of examples.

[0129] Discussion

[0130] This example provides approaches for supportive molecular cancer diagnoses that can be used for support of chronic myeloid leukemia patients, including through the Spot on CML program with the MAX foundation (Sala Torra O, el al. Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. Blood. 2016; 127(22):2773-4). The approaches disclosed herein answer the need to provide testing that, is more portable with a faster turnaround time, tests that, can be done closer to patients, and platforms that can assay several targeted genes simultaneously. The disclosed example rapid assays can be used to detect fusion genes in blood or marrow samples in 8-12 hours or less. For example, an actual time to achieve three fusion reads was 5 hours on a portable sequencing device with an accessible cloud-based data analysis workflow. This was accomplished by combining CRISPR-Cas9 enrichment during library preparation, nanopore long-read sequencing, and a cloud-based data analysis pipeline with a novel BFF program developed and optimized for finding fusion reads and breakpoints. RNA guides were designed to target genes involved in recurrent fusions in myeloid malignancies and used to enrich an amplification-free library preparation over 1600-fold. This disclosed modular and containerized pipeline in Bwb allows users to efficiently process raw FAST5 data on the cloud through an accessible graphical user interface, allowing for a very fast, analysis step (average ~4.5 minutes for base calling, alignment, and fusion detection). To improve fusion calling, the custom BFF software as described herein allows users to identify fusion reads not detected by LongGF. Published genomic breakpoints in a series of cell lines and archival patient samples were confirmed, including both diagnostic and follow-up samples, to test feasibility in confirming both common and novel fusions over a range of tumor burdens. This example includes 14 patient specimens and demonstrates the usability of this method in primary specimens with 2 micrograms of DNA.

[0131] An advantage of the CRISPR-Cas9 based enrichment protocol is that it allows targeting multiple common leukemia fusion genes by pooling multiple guide RNAs. While any genomic aberration can be interrogated, fusions are particularly well suited for the disclosed methods, as they have large gene segments that aid in alignment despite sequencing errors and wide variations where translocation breakpoints may occur.

[0132] Previous efforts have employed methods that detected fusions by targeting one partner gene in the fusion (Stangl C, el al., Partner independent fusion gene detectionby multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing. Nat Commun. 2020;l 1(1):2861); in contrast, the disclosed assays target both fusion partners; thus this approach allows for an expanded capability to detect known and novel fusions, such as in the case of AML1 with t(9;l l), when guides are designed to target t(4;l 1). However, in 2 / 14 patients, the assay did not detect fusion genes, because both cases had a very low amount of fusion target. In one case (CML3) because the BCR::ABL1 was <0.01%, the other was in the context of a very hypocellular sample.

[0133] Embodiments of the present disclosure differ from and improve upon previous RNA-based fusion detection assays, and instead interrogates single molecules of DNA rapidly and accurately to detect specific translocation breakpoints. Long-read sequencing technologies, like Nanopore® (Oxford Nanopore Technologies®, Oxford, U.K.), allow the sequencing of unamplified, long unbroken fragments of DNA which can be more likely to span a breakpoint. This genomic breakpoint identification has potential clinical utility for personalized disease monitoring when CML patients are on TKI therapy and suppressing RNA transcription (Pagani IS, et al. BCR-ABL1 genomic DNA PCR response kinetics during first-line irnatinib treatment of chronic myeloid leukemia. Haematologica. 2018; 103(12):2026-32.), targeting DNA as a monitoring target, which can be more robust and reproducible, since DNA is stable and present in constant numbers (Ross DM, et al.. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping irnatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):l 719-24.). The disclosed methods that involve targeting DNA, rather than RNA, benefit from a higher tolerance for challenged samples, and in addition, testing tissues with poor preservation is possible, which is especially beneficial for LMICs and remote areas that may not have immediate access to a pathology laboratory or even refrigeration. However, genomic breakpoints in BCR::ABL1 are unique to individual patients involving patient-specific breakpoint characterization (Ross DM, el al.. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping irnatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010,24(10): 1719-24, Zhang JG, et al., Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood. 1996;87(6):2588-93; Mattarucchi E, et al.Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA. compared with conventional mRNA analysis. J Mol Diagn. 2009; 11(5):482-7; Bartley PA, et al., A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. J Mol Diagn. 2015;17(2): 185-92; Bartley PA, et al., Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR- ABL DNA. IntJ Lab Hematol. 2010;32(6 Pt 1 ):e222-8), as ABLl breakpoints occur over an expansive region of about 150Kb, making this an arduous endeavor previously involving multiple primer sets and Sanger sequencing (Gumbo C, et al., Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances. Cancer Manag Res. 2020;12:3175-89). The disclosed methods enable a single approach, spanning the BCR and ABL1 breakpoint regions, without the use of multiple primers and PCR reactions. Once the breakpoint is known, the sensitivity of DNA-based qPCR can be as low' as 10~7. (Burmeister T, et al., Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20(3):451-7; Branford S. Molecular monitoring in chronic myeloid leukemia-how low can you go? Hematology Am. Soc Hematol Educ Program. 2016;2016(l): 156-63) Specimens CML1 and CML5 are a BM and PB (respectively) obtained from the same patient and demonstrate high fidelity in confirming genomic breakpoints and the ability to use patient-specific primers for personalized MRD monitoring.

[0134] Advantages of long-read sequencing methods of this disclosure over previous clinical diagnostic assays include speed and the relatively low complexity of the assay, including when compared to cytogenetics and targeted NGS panels. While long-read sequencing results could potentially have a turnaround time (TAT) of less than 24 hours, full karyotype analysis TAT is generally longer, with the fastest times at days to a week, and most targeted NGS panels include -7-10 days from the start of processing to the result report. The nanopore sequencing generates data that can be simultaneously analyzed by a GPU-enabled data analytic pipeline in the Bwb interface, which resides on the cloud to help interpret and reliably identify fusion reads within 5000 seconds (<2 hours) of computational time in most specimens. Building on prior experience, three reads were used as a threshold for fusion confirmations. With the simultaneous sequencing and data analysisworkflow described here, three sequences were detected in an average of 3 hours and 7 minutes (fastest at 30 minutes) in the nine patient specimens where a fusion could be confirmed. Consequently, with any of the disclosed approaches, a diagnostic result with a precise fusion breakpoint with three fusion supporting reads can be possible on the same day.

[0135] Conclusion

[0136] This example demonstrates the feasibility of using single molecule long- range sequencing assay to detect fusion genes in patients with heme malignancies (AML, CML and APL). Characteristics of fusions make this assay a promising, cost-effective tool for rapid detection of recurrent fusions that I) involve previous knowledge of only one of two target genes as guides can capture an unknown partner gene, 2) has a rapid TAT (8 hours in 80% of samples) when multiplexing different assays and used with the specific data analysis and fusion detection tools, 3) can precisely map translocation genomic breakpoints that enable development of personalized markers for disease monitoring, and 4) can enable discovery of novel / different fusion partners. The disclosed example shows that, a low-cost, portable fusion cancer diagnostic device with an integrated cloud-based on-demand analysis workflow7can be implemented in LMICs. Furthermore, no expensive lab investment or computing infrastructures is necessarily needed, thus bridging the gap between diagnosis and tailored treatment administration.KIT, DEVICE, SYSTEM, CIRCUITRY, PROCESSOR, AND COMPUTER IMPLEMENTATIONS

[0137] Accordingly, in various aspects, all or part of methods, compositions, circuitry, non-transitory computer-readable storage media, instructional materials, and the like, can be integrated into certain commercially-relevant form factors, such as kits, products, devices, computational devices, systems, computational systems, processorexecutable code, firmware, software, circuitry', and others.

[0138] Accordingly, embodiments of devices and any systems disclosed herein, including embodiments that, include or utilize a processor and / or processor executable instructions can utilize circuitry to implement those technologies and methodologies. Such circuitry7can operatively connect two or more components, generate information,determine operation conditions, control an appliance, device, or method, and / or the like. Circuitry of any type can be used. In embodiments, circuitry includes dedicated hardware having electronic circuitry configured to perform operations or computations on a dedicated basis, without any use of microprocessors, central processing units, or software or firmware or processor-executable instructions. However, in embodiments, circuitry includes, among other things, one or more computing devices such as one or more processors (e.g., microprocessor s)), one or more central processing units (CPU), one or more digital signal processors (DSP), one or more application-specific integrated circuits (ASIC), one or more field-programmable gate arrays (FPGA), or the like, or any variations or combinations thereof, and can include discrete digital and / or analog circuit elements or electronics, or combinations thereof.

[0139] In embodiments, circuitry' includes one or more ASICs having a plurality of predefined logic components. In embodiments, circuitry includes one or more FPGA having a plurality of programmable logic components. In embodiments, circuitry includes hardware circuit implementations (e.g, implementations in analog circuitry, implementations in digital circuitry', and the like, and combinations thereof). In embodiments, circuitry includes combinations of circuits and computer program products having software or firmware processor-executable instructions stored on one or more computer readable memories, e.g., non-transitory computer-readable storage mediums, that work together to cause a device or system to perform one or more methodologies or technologies described herein,

[0140] In embodiments, circuitry includes circuits, such as, for example, microprocessors or portions of microprocessors, that require software, firmware, and the like for operation. In embodiments, circuitry includes an implementation comprising one or more processors or portions thereof and accompanying software, firmware, hardware, and the like. In embodiments, circuitry' includes a baseband integrated circuit or applications processor integrated circuit or a similar integrated circuit in a server, a cellular network device, other network device, or other computing device. In embodiments, circuitry' includes one or more remotely located components. In embodiments, remotely located components (e.g., server, server cluster, server farm, virtual private network, etc.) are operatively connected via wired and / or wireless communication to non-remotelylocated components (e.g., desktop computer, workstation, mobile device, controller, etc.). In embodiments, remotely located components are operatively connected via one or more receivers, transmitters, transceivers, or the like.

[0141] Embodiments include one or more data stores that, for example, store instructions and / or data. Non-limiting examples of one or more data stores include volatile memory' (e.g.. Random Access memory (RAM), Dynamic Random Access memory (DRAM), or the like), non-volatile memory (e.g., Read-Only memory’ (ROM), Electrically Erasable Programmable Read-Only memory (EEPROM), Compact Disc Read-Only memory (CD-ROM), or the like), persistent memory, or the like. Further non-limiting examples of one or more data stores include Erasable Programmable Read-Only memory (EPROM), flash memory, or the like. The one or more data stores can be connected to, for example, one or more computing devices by one or more instructions, data, or power buses.

[0142] In embodiments, circuitry' includes one or more computer-readable media drives, interface sockets, Universal Serial Bus (USB) ports, memory' card slots, or the like, and one or more input / output components such as, for example, a graphical user interface, a display, a keyboard, a keypad, a trackball, a joystick, a touch-screen, a mouse, a switch, a dial, or the like, and any other peripheral device. In embodiments, circuitry includes one or more user input / output components that are operatively connected to at least one computing device to control (electrical, electromechanical, software-implemented, firmware-implemented, or other control, or combinations thereof) one or more aspects of the embodiment.

[0143] In embodiments, circuitry' includes a computer-readable media drive or memory' slot configured to accept signal -bearing medium (e.g., computer-readable memory' media, computer-readable recording media, or the like). In embodiments, a program for causing a system to execute any of the disclosed methods can be stored on, for example, a computer-readable recording medium (CRMM), a signal -bearing medium, or the like. Nonlimiting examples of signal-bearing media include a recordable type medium such as any form of flash memoiy, magnetic tape, floppy disk, a hard disk drive, a Compact Disc (CD), a Digital Video Disk (DVD), Blu-Ray Disc, a digital tape, a computer memory, or the like, as well as transmission type medium such as a digital and / or an analog communication medium (e.g., a fiber optic cable, a waveguide, a wired communications link, a wirelesscommunication link (e.g., transmitter, receiver, transceiver, transmission logic, reception logic, etc.). Further non-limiting examples of signal-bearing media include, but are not limited to, DVD-ROM, DVD-RAM, DVD+RW, DVD-RW, DVD-R, DVD+R, CD-ROM, Super Audio CD, CD-R, CD+R, CD+RW, CD-RW, Video Compact Discs, Super Video Discs, flash memoiy, magnetic tape, magneto-optic disk, MINIDISC, non-volatile memory card, EEPROM, optical disk, optical storage, RAM, ROM, system memory, web server, or the like.TERMINOLOGY

[0144] Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present discl osure. Practitioners are particularly directed to Sambrook J., et al. (eds.), Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Press, Plainsview, New York (2001); and Ausubel, F.M., etal. (eds. ), Current Protocols in Molecular Biology, John Wiley & Sons, New York (2010); for definitions and terms of art.

[0145] The use of the term "or" in the claims is used to mean "and / or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and / or." The words "a" and "an," when used in conjunction with the word "comprising" in the claims or specification, denotes one or more, unless specifically noted.

[0146] Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise," "comprising," and the like, are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to indicate, in the sense of "including, but not limited to." Words using the singular or plural number also include the plural and singular number, respectively. Additionally, the words "herein," "above," and "below," and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of the application.

[0147] In at least some embodiments, ‘"about” refers to the stated value and a range that includes values 10% below the stated value to 10% above the stated value. In embodiments, “about” refers to the stated value and a range that includes values 11% below the stated value, 12% below the stated value, 13% below the stated value, 14% below thestated value, 15% bel ow the stated value, 16% below the stated value, 17% below the stated value, 18% below the stated value, 19% below the stated value, 20% below the stated value, 21% below the stated value, 22% below the stated value, 23% below the stated value, 24% below the stated value, or 25% below the stated value. In embodiments, “about” refers to the stated value and a range that includes values 11% above the stated value, 12% above the stated value, 13% above the stated value, 14% above the stated value, 15% above the stated value, 16% above the stated value, 17% above the stated value, 18% above the stated value, 19% above the stated value, 20% above the stated value, 21% above the stated value, 22% above the stated value, 23% above the stated value, 24% above the stated value, or 25% above the stated value.

[0148] The terms “subject," "individual," and "patient" are used interchangeably herein to refer to a mammal being assessed for treatment and / or being treated. In certain embodiments, the mammal is a human. The terms "subject," "individual," and "patient" encompass, without limitation, individuals having cancer. While subjects may be human, the term also encompasses other mammals, particularly those mammals useful as laboratory models for human disease, e.g, mouse, rat, dog, non-human primate, and the like.

[0149] The term "treating" and grammatical variants thereof may refer to any indicia of success in the treatment or amelioration or prevention of a disease or condition (e.g., a cancer, infectious disease, or autoimmune disease), including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the disease condition more tolerable to the patient; slowing in the rate of degeneration or decline; or making the final point of degeneration less debilitating.

[0150] The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of an examination by a physician. Accordingly, the term "treating" includes the administration of one or more compounds or agents to a subject to prevent or delay, to alleviate, to improve clinical outcomes, to decrease occurrence of symptoms, to improve quality of life, to lengthen disease-free status, to stabilize, to prolong survival, to arrest or inhibit development of the symptoms or conditions associated with a disease or condition (e.g., a cancer), or any combination thereof, in the subject. The term "therapeutic effect" refers to the reduction, elimination, orprevention of the disease or condition, symptoms of the disease or condition, or side effects of the disease or condition in the subject.

[0151] As used herein, the terms "nucleic acid" or "polynucleic acid" refer to a polymer of nucleotide monomer units or "residues", typically DNA or RNA. The nucleotide monomer subunits, or residues, of the nucleic acids each contain a nitrogenous base (i.e., nucleobase) a five-carbon sugar, and a phosphate group. The identity of each residue is typically indicated herein with reference to the identity of the nucleobase (or nitrogenous base) structure of each residue. Canonical nucleobases include adenine (A), guanine (G), thymine (T), uracil (U) (in RNA instead of thymine (T) residues) and cytosine (C). However, the nucleic acids of the present disclosure can include any modified nucleobase, nucleobase analogs, and / or non-canonical nucleobase, as are well-known in the art.

[0152] Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. It is understood that, when combinations, subsets, interactions, groups, etc., of these materials are disclosed, each of various individual and collective combinations is specifically contemplated, even though specific reference to each and even,- single combination and permutation of these compounds may not be explicitly disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in the described methods. Thus, specific elements of any foregoing embodiments can be combined or substituted for elements in other embodiments. For example, if there are a variety of additional steps that can be performed, it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed. Additionally, it is understood that the embodiments described herein can be implemented using any suitable material such as those described elsewhere herein or as known in the art.

[0153] Publications cited herein and the subject matter for which they are cited are hereby specifically incorporated by reference in their entireties.TABLES

[0154] Table 1. Characteristics of the primary specimens analyzed with library preparation and sequencing assay.Table 2. Characteristics of the runs.

[0156] Table 3. Enrichment characteristics and comparison of fusion detection by BFF versus long GF.i i i i | i i i i i i

[0157] Table 4. Times and total reads before 3 fusion reads can be confirmed in cell lines and patient samples.

[0158] Table 5. Targets of CRISPR guides of the disclosure. The table includes the significance of the target, specifically, if there are prognostic and treatment implications, the incidence they are seen in AML, and the references specific to that marker. The references of Table 5 are incorporated by reference herein.

[0159] Table 6. Example CRISPR guide sequences of the disclosure.

[0160] Table 7. Example target sequences of the disclosure.NON-LIMITING EMBODIMENTS

[0161] While general features of the disclosure are described and shown and particular features of the disclosure are set forth in the claims, the following non-limiting embodiments relate to features, and combinations of features, that are explicitly envisioned as being part of the disclosure. The following non-limiting Embodiments contain elements that are modular and can be combined with each other in any number, order, or combination to form a new non-limiting Embodiment, which can itself be further combined with other non-li m iti ng Emb odi m ents .

[0162] Embodiment 1. A method of treating a subject with a leukemia, the method comprising: contacting a DNA molecule that comprises a leukemia gene mutation or alteration with an endonuclease-guide RNA complex to generate a long-chain DNA molecule that comprises the leukemia gene mutation or alteration; sequencing, without amplification of the long-chain DNA molecule, the long chain DNA molecule with a long- range sequencing method to produce a sequence read, computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read, wherein the characteristic corresponds to the leukemia, and administering a leukemia treatment to the subject based on the characteristic.

[0163] Embodiment 2. A method of diagnosing a subject with a leukemia, the method comprising: contacting a DNA molecule that comprises a leukemia gene mutation with an endonuclease-guide RNA complex to generate a long-chain DNA molecule that comprises the leukemia gene mutation, sequencing, without amplification of the long-chain DNA molecule, the long-chain DNA molecule with a long-range sequencing method to produce a sequence read; computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read, wherein the characteristic corresponds to the leukemia; and diagnosing the subject with the leukemia based on the characteristic.

[0164] Embodiment 3. The method of any one of Embodiments 1-2 or any other Embodiment, wherein the leukemia comprises acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), myeloproliferative neoplasm (MPN), mixed-lineage leukemia (MLL), or any combination thereof.

[0165] Embodiment 4. The method of any one of Embodiments 1-3 or any other Embodiment, wherein the characteristic comprises a genetic mutation, a deletion, an insertion, a substitution, a frameshift, a breakage, a fusion, a genetic phase change, or any combination thereof.

[0166] Embodiment 5. The method of any one of Embodiments 1-4 or any other Embodiment, wherein the leukemia gene mutation comprises: an ASXL transcriptional regulator 1 (ASXL1) mutation, an fms related receptor tyrosine kinase 3 (FLT3) mutation, a CCAAT enhancer binding protein alpha (CEBPA) mutation, a nucleophosmin 1 (NPM1) mutation, an isocitrate dehydrogenase (NADP(+)) 1 / 2 (IDH1 / 2) mutation, a calreticulin (CALR) mutation, a KIT proto-oncogene receptor tyrosine kinase (KIT) mutation, a Janus kinase 2 (JAK2) mutation, a tumor protein P53 (TP53) mutation, a t( 15; 17)(q24.1 ;q21.2) PML-retinoic acid receptor alpha (RARA) translocation that forms a fusion gene, a t(8;21)(q22;q22.1) RUNX family transcription factor 1 (RUNX1)- RUNX1 partner transcriptional co-repressor 1 (RUNX1T1) translocation that forms a fusion gene, a translocation between core-binding factor subunit beta (CBFB)-myosin heavy chain 11 (MYH11) (inv!6) that forms a fusion gene, a t(6;9) translocation between genes DEK protooncogene (DEK)-nucleoporin 214 (NUP214) that forms a fusion gene, a t(l;22) translocation between genes DEK protooncogene (DEK) and nucleoporin 214 (NUP214) that forms a fusion gene, a translocation t(9;22)(q34;ql 1) between breakpoint cluster region (BCR) and Ableson murine leukemia viral oncogene homolog 1 (ABL1) that results in a fusion gene, a non-receptor tyrosine kinase (ABL 1 ) mutation, a translocation between nucleoporin 98 and 96 precursor (NUP98) to nuclear receptor binding SET domain protein1 (NSD1) that results in a fusion gene, an MLL rearrangement that results in a fusion gene, or any combination thereof.

[0167] Embodiment 6. The method of any one of Embodiments 1-5 or any other Embodiment, wherein the leukemia gene mutation comprises: the PML-RARA mutation, the ABL1 mutation, the MLL mutation, a fusion that involves at least one gene rearrangement of one or more genes of any one of Embodiments 1-5, or any combination thereof

[0168] Embodiment 7. The method of any one of Embodiments 1-6 or any other Embodiment, wherein the endonuclease-guide RNA complex comprises a guide RNA (gRNA) comprising a sequence selected from SEQ ID NOs: 1-70.

[0169] Embodiment 8. The method of any one of Embodiments 1-7 or any other Embodiment, wherein the long-chain DNA molecule comprises a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

[0170] Embodiment 9. The method of any one of Embodiments 1-8 or any other Embodiment, wherein the long-chain DNA molecule is not amplified by any polymerase chain reaction (PCR) technique or any isothermal DNA amplification technique.

[0171] Embodiment 10. The method of any one of Embodiments 1-9 or any other Embodiment, wherein one or more leukemia treatment compositions is administered to the subject for treatment of the leukemia.

[0172] Embodiment 11. The method of Embodiment 10 or any other Embodiment, wherein the one or more leukemia treatment compositions comprises an FLT3 inhibitor, an IDH1 inhibitor, an IDH2 inhibitor, a Jak2 inhibitor, an HD AC inhibitor, all-transretinoic acid (ATRA), an anti-CD33 targeted therapeutic compound, a tyrosine kinase inhibitor, a chemotherapeutic compound, a DOTI L inhibitor, or any combination thereof.

[0173] Embodiment 12. The method of Embodiment 11 or any otherEmbodiment, wherein the FLT3 inhibitor comprises midostaurin, gilteritinib, or both.

[0174] Embodiment 13. The method of Embodiment 11 or any other Embodiment, wherein the IDH1 inhibitor comprises ivosidenib.

[0175] Embodiment 14. The method of Embodiment 11 or any otherEmbodiment, wherein the IDH2 inhibitor comprises enasidenib.

[0176] Embodiment 15. The method of Embodiment 11 or any otherEmbodiment, wherein the one or more leukemia treatment compositions comprises the Jak2 inhibitor and the HD AC inhibitor.

[0177] Embodiment 16. The method of Embodiment 11 or any other Embodiment, wherein the one or more leukemia treatment compositions comprises the ATRA and the anti-CD33 targeted therapeutic compound.

[0178] Embodiment 17. The method of Embodiment 11 or any other Embodiment, wherein the tyrosine kinase inhibitor comprises dasatinib, imatinib, midostaurin, or any combination thereof.

[0179] Embodiment 18. Circuitry' configured for performance of a method, the method comprising: downloading, from a cloud computing device, genomic data that is relevant to leukemia; electronically storing raw sequence data to a non-transitory computer-readable storage medium as non-transitory data; basecalling the non-transitory data that comprises the raw sequence data to produce nucleotide base data that correspond to nucleotide bases of a sequenced long chain DNA molecule; indexing and aligning the nucleotide base data with alignment data and gene definition data for an alignment; computing, from the alignment, one or more leukemia gene aberrations of the sequenced long-chain DNA molecule, wherein the one or more leukemia gene aberrations is inclusive of leukemia gene aberrations that are proximal and distal to a leukemia gene breakpoint; and depicting, with an electronic display, the alignment and the one or more leukemia gene aberrations of the sequenced long-chain DNA molecule.

[0180] Embodiment 19. The circuitry of Embodiment 18 or any other Embodiment, wherein at least the computing of the one or more leukemia gene aberrations is performed by a Biodepot Fusion Finder (BFF) software that configures the circuitry’ to compute fusion enrichment and on-target enrichment statistics for the computing of the one or more leukemia gene aberrations.

[0181] Embodiment 20. One or more computational devices or systems comprising the circuitry' of any one of Embodiments 18-19 or any other Embodiment.

[0182] Embodiment 21. A guide RNA comprising a sequence as set forth in any one of SEQ ID NOs: 1-70.

[0183] Embodiment 22. The guide RNA of Embodiment 21 or any other Embodiment, wherein the guide RNA is configured to bind a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

[0184] Embodiment 23. An endonuclease-guide RNA complex comprising the guide RNA of any one of Embodiments 21-22 or any other Embodiment.

[0185] Embodiment 24. A composition comprising the endonuclease-guide RNA complex of Embodiment 23 or any other Embodiment.

[0186] Embodiment 25. A kit comprising the composition of Embodiment 24 or any other Embodiment and an instructional material configured to instruct a user for a use of the kit in performance of a method.

[0187] Embodiment 26. A probe for detecting a leukemia gene mutation, the probe comprising a sequence as set forth in any one of SEQ ID NOs: 1-70.

[0188] Embodiment 27. The probe of Embodiment 26 or any other Embodiment, wherein the probe binds to a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

[0189] Embodiment 28. A library comprising a plurality of endonucleaseguide RNA complexes of Embodiment 23 or any other Embodiment, wherein eachendonuclease-guide RNA complex comprises a guide RNA that targets DNA that comprises a leukemia gene mutation.

[0190] While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the disclosure.

Claims

CLAIMSThe embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of treating a subject with a leukemia, the method comprising: contacting a DNA molecule that comprises a leukemia gene mutation or alteration with an endonuclease-guide RNA complex to generate a long-chain DNA molecule that comprises the leukemia gene mutation or alteration; sequencing, without amplification of the long-chain DNA molecule, the long-chain DNA molecule with a long-range sequencing method to produce a sequence read; computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read, wherein the characteristic corresponds to the leukemia; and administering a leukemia treatment to the subject based on the characteristic.

2. A method of diagnosing a subject with a leukemia, the method comprising: contacting a DNA molecule that comprises a leukemia gene mutation with an endonuclease-guide RNA complex to generate a long-chain DNA molecule that comprises the leukemia gene mutation; sequencing, without amplification of the long-chain DNA molecule, the long-chain DNA molecule with a long-range sequencing method to produce a sequence read; computing, with a computational method, a characteristic of the leukemia gene mutation within the DNA molecule based on the sequence read, wherein the characteristic corresponds to the leukemia; and diagnosing the subject with the leukemia based on the characteristic.

3. The method of any one of claims 1 -2, wherein the leukemia comprises acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), myeloproliferative neoplasm (MPN), mixed-lineage leukemia (MLL), or any combination thereof.

4. The method of any one of claims 1-3, wherein the characteristic comprises a genetic mutation, a deletion, an insertion, a substitution, a frameshift, a breakage, a fusion, a genetic phase change, or any combination thereof.

5. The method of any one of claims 1-4, wherein the leukemia gene mutation comprises: an ASXL transcriptional regulator 1 (ASXL1) mutation, an fms related receptor tyrosine kinase 3 (FLT3) mutation, a CCAAT enhancer binding protein alpha (CEBPA) mutation, a nucleophosmin 1 (NPM1) mutation, an isocitrate dehydrogenase (NADP(+)) 1 / 2 (IDH1 / 2) mutation, a calreticulin (CALR) mutation, a KIT proto-oncogene receptor tyrosine kinase (KIT) mutation, a Janus kinase 2 (JAK2) mutation, a tumor protein P53 (TP53) mutation, a t(15;17)(q24.1;q21.2) PML-retinoic acid receptor alpha (RARA) translocation that forms a fusion gene, a t(8;21)(q22;q22.1) RUNX family transcription factor 1 (RUNX1)- RUNX1 partner transcriptional co-repressor 1 (RUNX1T1) translocation that forms a fusion gene, a translocation between core-binding factor subunit beta (CBFB)-myosin heavy chain 11 (MYH11) (inv!6) that forms a fusion gene, a t(6;9) translocation between genes DEK protooncogene (DEK)-nucleoporin 214 (NUP214) that forms a fusion gene, a t(l;22) translocation between genes DEK protooncogene (DEK) and nucleoporin 214 (NUP214) that forms a fusion gene, a translocation t(9;22)(q34;ql 1) between breakpoint cluster region (BCR) and Ableson murine leukemia viral oncogene homolog 1 (ABL 1 ) that results in a fusion gene, a non-receptor tyrosine kinase (ABL 1 ) mutation, a translocation between nucleoporin 98 and 96 precursor (NLJP98) to nuclear receptor binding SET domain protein 1 (NSDl) that results in a fusion gene, an MLL rearrangement that results in a fusion gene, or any combination thereof.

6. The method of any one of claims 1-5, wherein the leukemia gene mutation comprises: the PML-RARA mutation, the AB LI mutation, the MLL mutation, a fusion that, involves at least one gene rearrangement of one or more genes of any one of claims 1-5, or any combination thereof.

7. The method of any one of claims 1 -6, wherein the endonuclease-guide RNA complex comprises a guide RNA (gRNA) comprising a sequence selected from SEQ ID NOs: L70.

8. The method of any one of ctaims 1-7, wherein the long-chain DNA molecule comprises a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71~140.

9. The method of any one of claims 1-8, wherein the long-chain DNA molecule is not amplified by any polymerase chain reaction (PCR) technique or any isothermal DNA amplification technique.

10. The method of any one of claims 1-9, wherein one or more leukemia treatment compositions is administered to the subject for treatment of the leukemia.

11. The method of claim 10, wherein the one or more leukemia treatment compositions comprises an FLT3 inhibitor, an 11)1 11 inhibitor, an IDH2 inhibitor, a Jak2 inhibitor, an HD AC inhibitor, all-transretinoic acid (ATRA), an anti-CD33 targeted therapeutic compound, a tyrosine kinase inhibitor, a chemotherapeutic compound, a DOT IL inhibitor, or any combination thereof.

12. The method of claim 11 , wherein the FLT3 inhibitor comprises midostaurin, gilteritinib, or both.

13. The method of claim 11, wherein the IDH1 inhibitor comprises ivosidenib.

14. The method of claim 11, wherein the IDH2 inhibitor comprises enasidenib.

15. The method of claim 11, wherein the one or more leukemia treatment compositions comprises the Jak2 inhibitor and the HD AC inhibitor.

16. The method of claim 11, wherein the one or more leukemia treatment compositions comprises the ATRA and the anti-CD33 targeted therapeutic compound.

17. The method of claim 11, wherein the tyrosine kinase inhibitor comprises dasatinib, imatinib, midostaurin, or any combination thereof.

18. Circuitry configured for performance of a method, the method comprisingdownloading, from a cloud computing device, genomic data that is relevant to leukemia; electronically storing raw sequence data to a non-transitory computer-readable storage medium as non-transitory data; basecalling the non-transitory data that comprises the raw sequence data to produce nucleotide base data that, correspond to nucleotide bases of a sequenced long-chain DNA molecule; indexing and aligning the nucleotide base data with alignment data and gene definition data for an alignment; computing, from the alignment, one or more leukemia gene aberrations of the sequenced long-chain DNA molecule, wherein the one or more leukemia gene aberrations is inclusive of leukemia gene aberrations that are proximal and distal to a leukemia gene breakpoint; and depicting, with an electronic display, the alignment and the one or more leukemia gene aberrations of the sequenced long-chain DNA molecule.

19. The circuitry of claim 18, wherein at least the computing of the one or more leukemia gene aberrations is performed by a Biodepot Fusion Finder (BFF) software that configures the circuitry to compute fusion enrichment and on-target enrichment statistics for the computing of the one or more leukemia gene aberrations.

20. One or more computational devices or systems comprising the circuitry of any one of claims 18-19.

21. A guide RNA comprising a sequence as set forth in any one of SEQ ID NOs: 1-70.

22. The guide RNA of claim 21, wherein the guide RNA is configured to bind a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

23. An endonuclease-guide RNA complex comprising the guide RNA of any one of claims 21-22.A. A composition comprising the endonuclease-guide RNA complex of claim23.

25. A kit comprising the composition of ciaim 24 and an instructional material configured to instruct a user for a use of the kit in performance of a method.

26. A probe for detecting a leukemia gene mutation, the probe comprising a sequence as set forth in any one of SEQ ID NOs:l-70.

27. The probe of claim 26, wherein the probe binds to a target sequence comprising a sequence as set forth in any one of SEQ ID NOs:71-140.

28. A library comprising a plurality of endonuclease-guide RNA complexes of claim 23, wherein each endonuclease-guide RNA complex comprises a guide RNA that targets DNA that comprises a leukemia gene mutation.

Citation Information

Patent Citations

  • Methods and compositions for disease prognosis based on nucleic acid methylation

    US20090317801A1

  • Compositions for characterizing development of esophageal adenocarcinoma in patients and methods of use thereof

    US20190100803A1